<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Colorectal Dis</journal-id><journal-id journal-id-type="iso-abbrev">Int J Colorectal Dis</journal-id><journal-title-group><journal-title>International Journal of Colorectal Disease</journal-title></journal-title-group><issn pub-type="ppub">0179-1958</issn><issn pub-type="epub">1432-1262</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40000449</article-id><article-id pub-id-type="pmc">PMC11861249</article-id>
<article-id pub-id-type="publisher-id">4841</article-id><article-id pub-id-type="doi">10.1007/s00384-025-04841-w</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Predicting extensive metastasis in postoperative oligometastatic colorectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fan</surname><given-names>Rencai</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mao</surname><given-names>Chenkai</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Jiaqi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dai</surname><given-names>Min</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Rong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xinran</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dai</surname><given-names>Jiaxin</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Shicheng</given-names></name><address><email>lishcheng@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhuang</surname><given-names>Zhixiang</given-names></name><address><email>13951106391@139.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02xjrkt08</institution-id><institution-id institution-id-type="GRID">grid.452666.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1762 8363</institution-id><institution>Center for Cancer Diagnosis and Treatment, </institution><institution>The Second Affiliated Hospital of Soochow University, </institution></institution-wrap>No.1055, Sanxiang Road, Gusu District, Soochow, 215004 Jiangsu Province P.R. China </aff><aff id="Aff2"><label>2</label>Department of Respiratory Medicine, Wu Zhong People&#x02019;s Hospital, No. 61 Dongwu North Road, Wu Zhong District, Soochow, 215100 Jiangsu Province P.R. China </aff><aff id="Aff3"><label>3</label>Department of Oncology, The Nuclear Industry 417 Hospital, No. 5 Kangfu Road, Lintong District, Xi&#x02019;an, Shaanxi Province 710600 P.R. China </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>40</volume><issue>1</issue><elocation-id>53</elocation-id><history><date date-type="accepted"><day>16</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">Oligometastatic colorectal cancer (OMCRC) patients can achieve long-term disease control with multidisciplinary treatment. However, the development of extensive metastasis worsens prognosis and restricts treatment options. This study aims to develop a predictive model for extensive metastasis in OMCRC to assist in clinical decision-making.</p></sec><sec><title>Methods</title><p id="Par2">Clinical and pathological data for OMCRC patients were collected from the Second Affiliated Hospital of Soochow University. Patients were randomly divided into training and testing cohorts. Risk factors for extensive metastasis were identified through LASSO regression analysis and COX regression analysis. Three predictive models were developed in the training cohort and validated in the testing cohort: COX regression analysis, Extreme Gradient Boosting (XGBoost), and Survival Support Vector Machine (SurvSVM). Finally, the optimal model was visualized with the nomogram.</p></sec><sec><title>Results</title><p id="Par3">A total of 214 patients with OMCRC were enrolled in the study. Four independent risk factors were identified: whether surgery has been undertaken following oligometastasis (WST), histological type (HT), carcinoembryonic antigen at the last follow-up (CAE at last-FU), and preoperative albumin to globulin ratio (Preop-AGR). In the testing cohort, the COX model (1-year AUC&#x02009;=&#x02009;0.82, 3-year AUC&#x02009;=&#x02009;0.72, 5-year AUC&#x02009;=&#x02009;0.85, mean AUC&#x02009;=&#x02009;0.80) performed best. Decision curve analysis (DCA) confirmed the net benefit of the Cox model, and the nomogram provided accurate predictions of metastasis risk.</p></sec><sec><title>Conclusion</title><p id="Par4">CAE at last-FU, Preop-AGR, HT, and WST are independent risk factors for extensive metastasis in OMCRC. The nomogram model incorporating risk factors can assist clinicians in developing optimal treatment for OMCRC patients.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00384-025-04841-w.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Colorectal cancer</kwd><kwd>Oligometastasis</kwd><kwd>Extensive metastasis</kwd><kwd>Risk factors</kwd><kwd>Prediction model</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">CRC (colorectal cancer) has become a significant public health challenge both in China and worldwide [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Approximately 15&#x02013;30% of CRC patients have metastases, and 20&#x02013;50% of initially localized CRC cases eventually develop metastases [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. The liver is the most common site of metastasis for CRC, followed by the lungs, peritoneum, and distant lymph nodes. Most patients with metastatic CRC are not candidates for R0 surgical resection and instead receive systemic therapy [<xref ref-type="bibr" rid="CR6">6</xref>], resulting in poorer prognoses [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par6">Numerous clinical studies have shown that patients with isolated liver metastasis from CRC can achieve long-term survival following surgery and systemic treatment [<xref ref-type="bibr" rid="CR9">9</xref>]. Similar outcomes have been observed in other secondary sites, such as lung metastases [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. The 2022 ESMO Clinical Practice Guidelines recommend that physicians assess whether patients with metastatic CRC are in a state of oligometastatic disease (OMD), defined as controlled primary tumor, all metastases being safely treatable by local methods, and metastases limited to no more than two sites [<xref ref-type="bibr" rid="CR7">7</xref>]. Similarly, the NCCN Guidelines guide clinical practice based on the resectability of metastases [<xref ref-type="bibr" rid="CR13">13</xref>]. In the treatment of OMCRC, a broader range of local therapies, such as radiotherapy and interventional techniques, are utilized for managing metastatic lesions, rather than relying solely on surgery. A multidisciplinary treatment approach that includes systemic chemotherapy, targeted therapy, surgical resection of metastases, and local ablation can offer patients the possibility of long-term disease control and even clinical cure [<xref ref-type="bibr" rid="CR4">4</xref>]. It is important to note that despite undergoing surgery and systemic treatment, 55 to 80% of patients with OMCRC will experience tumor recurrence and metastasis [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. For patients with persistent OMCRC, additional local and systemic treatments are still considered beneficial. However, when patients develop extensive multi-organ metastases, palliative systemic therapy is required, and the prognosis is often poorer. Therefore, identifying risk factors for the progression to extensive metastasis in patients with OMCRC and early prediction of extensive metastatic events are particularly crucial.</p><p id="Par7">Through retrospective studies and clinical trials, identifying prognostic risk factors and developing predictive models have become widely applied in cancer patient management. These tools include the Breast Cancer 21-Gene Recurrence Score, the Postoperative Recurrence Risk Score for CRC Liver Metastases, and the Endoscopic Resection Curative Scoring for Early Gastric Cancer, among others [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. Essentially, these tools stratify risk for specific patient subgroups, aiding in clinical follow-up, guiding patient prognosis expectations, or identifying high-risk individuals suitable for clinical trials. Extensive research indicates that clinical data such as TNM staging, tumor pathological parameters, serum tumor markers like CEA, and peripheral blood inflammatory markers are closely related to the prognosis of CRC. Prognostic models constructed from these clinical data also guide medical decision-making. However, there is relatively limited research on prognostic factors specific to OMCRC. Existing studies mainly focus on oligometastatic patients with specific organ metastases or on the risk of disease progression in oligometastatic patients. Furthermore, these studies emphasize preoperative measurements of various serum markers, while the utilization of dynamic measurement data throughout the disease progression is insufficient. This clearly overlooks the particularities of the oligometastatic state in CRC and the dynamic nature of the disease [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par8">This study retrospectively analyzed the clinical characteristics and longitudinal serological marker data of patients with oligometastatic colorectal cancer (OMCRC) treated at the Second Affiliated Hospital of Soochow University. The objective is to elucidate the correlation between these biomarkers and the risk of extensive metastasis and to develop a robust clinical prediction model. The model can facilitate personalized treatment planning, enable the accurate identification of OMCRC patients at high risk for extensive metastasis, and guide the implementation of optimal treatment and follow-up strategies, thereby enhancing patient outcomes and quality of life.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Study design</title><p id="Par9">The retrospective analysis comprehensively reviewed the medical records, hematological data, pathological information, and imaging results of 427 patients diagnosed with oligometastatic colorectal cancer at the Second Affiliated Hospital of Soochow University between January 1, 2005, and December 31, 2022. All patients were selected based on strict inclusion and exclusion criteria. Further exclusions included 23 patients with concurrent other malignancies undergoing antitumor treatment, 81 patients lacking detailed pathological information post-primary tumor surgery, and 109 patients with a follow-up period of less than 5&#x000a0;months. Ultimately, 214 patients met the study criteria. The detailed research process is outlined in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. In accordance with the Equator Network guidelines, this study adheres to the Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) guidelines and was approved by the Medical Ethics Committee of the Second Affiliated Hospital of Soochow University (approval number [JD-HG-2024&#x02013;034]). All patients provided informed consent upon admission, allowing their medical history, test results, and imaging data to be used for research purposes, with their personal information kept confidential.<fig id="Fig1"><label>Fig. 1</label><caption><p>Flowchart of the study</p></caption><graphic xlink:href="384_2025_4841_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec4"><title>Event definitions</title><p id="Par10">All patients underwent imaging examinations, including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography-computed tomography (PET-CT), or pathological examination of metastatic lesions, to confirm the diagnosis of OMCRC. For patients diagnosed with oligometastasis through imaging, a retrospective comparison was conducted, analyzing all imaging data, and the initial oligometastatic time was determined based on the first imaging evidence. Both synchronous and metachronous oligometastasis patients were included in the study, regardless of whether the metastatic lesions received treatment. Additionally, this study considers oligorecurrence as a special subtype of OMCRC and therefore includes patients with oligorecurrence in the analysis. Patients with no outcome events after the diagnosis of oligometastasis and a total follow-up time of less than 5&#x000a0;months, as well as those with other malignancies, were excluded from the study.</p><p id="Par11">In this study, patients with OMCRC were defined according to the traditional criteria set forth in the 2022 ESMO Clinical Practice Guidelines: primary tumors under control, 1 to 5 metastatic sites (if the metastatic sites can be safely treated, the number can exceed 5), and all metastatic sites amenable to local treatment with no more than 2 locations involved. OMCRC patients with a disease-free survival (DFS) of 6&#x000a0;months or less after radical surgery were classified as having synchronous OMCRC, while those with a DFS greater than 6&#x000a0;months were classified as having metachronous OMCRC. In this paper, patients with OMCRC refer to those who experience tumor recurrence at the colorectal site post-surgery, with recurrence sites meeting the criteria for oligometastasis (no further distinction will be made from OMCRC patients).</p><p id="Par12">In this study, an endpoint event is defined as the occurrence of extensive metastasis involving multiple sites after the diagnosis of OMCRC, including more than two metastatic sites, or two metastatic sites where the lesions are deemed inoperable upon evaluation [<xref ref-type="bibr" rid="CR4">4</xref>]. The primary endpoint for evaluating patient outcomes is the event-free survival (EFS), which is the time from the diagnosis of oligometastasis to the occurrence of the endpoint event. Follow-up time begins from the initial pathological diagnosis of CRC and continues until the patient experiences extensive metastasis, death, or loss to follow-up. Due to the limitations of this retrospective study in distinguishing whether deaths are cancer-related and the different risks associated with cancer-related deaths and extensive metastasis, both death and loss to follow-up are considered censored events in the analysis of risk factors for extensive metastasis.</p></sec><sec id="Sec5"><title>Clinical variables enrollment</title><p id="Par13">The candidate variables in this study are listed in Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>, with all variables based on clinical, epidemiological, or clinical research evidence. Serum marker data were collected at six time points: preoperative, postoperative, after the first postoperative treatment, at the time of oligometastasis, after oligometastasis treatment, and at the last follow-up. For patients with synchronous oligometastasis at the diagnosis of CRC, serum marker data were collected at four time points: preoperative (at the time of oligometastasis), postoperative, after the first postoperative treatment (after oligometastasis treatment), and at the last follow-up. Preoperative measurements refer to values within 4&#x000a0;weeks before the surgery, while postoperative measurements refer to values before the first antitumor treatment. If the patient did not receive antitumor treatment, measurements from the first follow-up within 4&#x000a0;weeks after surgery were used. To reduce the impact of myelosuppression following antitumor treatment, postoperative measurements were defined as values before the second antitumor treatment; if antitumor treatment was not given, measurements from the second follow-up within 4&#x000a0;weeks after surgery were used. Measurements at the time of metastasis refer to values within 2&#x000a0;weeks before and after the discovery of oligometastasis, while measurements after metastasis treatment refer to values before the second treatment after oligometastasis. Measurements at the last follow-up refer to values within 2&#x000a0;weeks before or after the occurrence of the outcome event; if the outcome event did not occur, the value closest to the censoring event was used. If tumor markers in the hematological data exceed the measurement limit, the measurement limit was recorded. In this study, there were 4 patients with T1 stage, 5 patients with clinical stage I, and 4 patients with well-differentiated adenocarcinoma, resulting in a small sample size and low statistical power. Therefore, T1 and T2 stages were combined into T1&#x02009;+&#x02009;2 stage; clinical stage I and clinical stage II were combined into clinical stage 1&#x02009;+&#x02009;2; moderately differentiated adenocarcinoma and well-differentiated adenocarcinoma were combined into moderately to well-differentiated adenocarcinoma.</p></sec><sec id="Sec6"><title>Data preprocessing</title><p id="Par14">Serum tumor marker data in cancer patients often exhibit extreme values and substantial variability among different patients due to disease progression. Additionally, the hematological data have varying magnitudes and ranges. Therefore, in this study, logarithmic transformation was applied to the hematological data [<xref ref-type="bibr" rid="CR28">28</xref>]. Similarly, due to the significant differences in the diameters (measured in mm) of oligometastatic lesions depending on their locations, the maximum diameter of these lesions was also logarithmically transformed. Logarithmic transformation reduces the absolute value of the data without altering its nature or relationships, enhancing the comparability of variables with different units, and improving normality and homogeneity of variance [<xref ref-type="bibr" rid="CR29">29</xref>]. The formula for the logarithmic transformation of serum tumor markers and the maximum diameter of oligometastatic lesions in this study is <italic>X</italic>1&#x02009;=&#x02009;ln(<italic>X</italic>); for blood cell counts, due to the presence of zero values, we used the formula <italic>X</italic>1&#x02009;=&#x02009;ln(<italic>X</italic>&#x02009;+&#x02009;2). Here, <italic>X</italic> represents the original value of the candidate variable, and <italic>X</italic>1 represents the value after logarithmic transformation for subsequent analysis.</p><p id="Par15">To address missing data under the assumption of missing at random, we used the Markov Chain Monte Carlo (MCMC) simulation method for multiple imputation [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>]. Variables with more than 40% missing data were excluded from the study, resulting in a final inclusion of 71 variables (Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref>). The imputation model incorporated all other candidate variables and outcome measures. For continuous data, we employed the predictive mean matching (PMM) method, iterating five times. For categorical data, we used the random forest (RF) method, also iterating five times. Post-imputation, we performed intergroup comparisons (Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref>), finding no statistically significant differences between any of the candidate variables (two-sided <italic>P</italic>-value&#x02009;&#x02265;&#x02009;0.05). Subsequent data analyses were conducted using these imputed data, and the platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), lymphocyte-albumin product (LA), albumin-globulin ratio (AGR), C-reactive protein-albumin ratio (CRA).</p></sec><sec id="Sec7"><title>Selection of risk factors</title><p id="Par16">The study employed a combination of LASSO and Cox proportional hazards regression analysis to investigate the risk factors for extensive metastasis following oligometastasis [<xref ref-type="bibr" rid="CR33">33</xref>]. The outcome was a binary variable, analyzed as a continuous variable in the regression analysis, with EFS treated as a time variable in Cox proportional hazards regression. The analysis included age, sex, reason for medical consultation (RMC), Clinical stage, TNM stage, tumor sidedness (TS), total number of detected lymph nodes (TNDLN), number of positive lymph nodes (NPLN), the number of cancerous nodules (NCN), HT, whether the tumor exhibits vascular invasion (WVI), whether the tumor exhibits neural invasion (WNI), whether the pathology indicates mucinous adenocarcinoma (WPMA), whether postoperative treatment is regular (WPTIS), postoperative treatment plan (PTP), OE, number of oligometastatic lesions (NOL), maximum diameter of oligometastatic lesions (MDOL), WST, and time-series features (CEA, CA50, CA125, CA199, RBC, PLR, LMR, LA, AGR, and CAR). Categorical variables were included in the regression analysis as dummy variables.</p><p id="Par17">The occurrence of extensive metastasis metastasis was used as the dependent variable, with EFS as the time variable. All candidate variables were included in the LASSO regression model and subjected to tenfold cross-validation. The optimal variables for the LASSO model were determined by examining Log(lambda) and partial likelihood deviance, and these variables were selected for further study [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par18">Univariate Cox proportional hazards regression analysis was conducted on the candidate variables selected by LASSO regression to explore their association with EFS. Hazard ratios (HR) and <italic>p</italic>-values were used as evaluation metrics. Variables with clinical or statistical significance from univariate analysis (HR&#x02009;&#x0003e;&#x02009;1.3 or&#x02009;&#x0003c;&#x02009;0.7, or <italic>p</italic>-value&#x02009;&#x0003c;&#x02009;0.05) were considered potential risk factors for EFS. Subsequently, multivariate Cox proportional hazards regression analysis was performed to adjust for potential risk factors and estimate adjusted <italic>p</italic>-values and HRs. Variables with a p-value&#x02009;&#x0003c;&#x02009;0.05 and HR&#x02009;&#x0003e;&#x02009;1.1 or HR&#x02009;&#x0003c;&#x02009;0.9 were considered independent risk factors for EFS. Finally, Kaplan&#x02013;Meier curves (KM curves) were used to validate the predictive value of each risk factor [<xref ref-type="bibr" rid="CR35">35</xref>]. The Log-rank test was employed to compare survival curves between groups for significant differences [<xref ref-type="bibr" rid="CR36">36</xref>].</p></sec><sec id="Sec8"><title>Model development</title><p id="Par19">A training cohort was created using a random sampling method, consisting of 136 patients. The unselected samples formed the testing cohort (<italic>n</italic>&#x02009;=&#x02009;78), while the original dataset (ALL cohort) served as the second testing cohort. All identified risk factors were included in the training cohort for model construction. Dummy variables were created for categorical variables. Three model construction methods were employed: Cox proportional hazards regression, eXtreme Gradient Boosting (XGBoost) survival analysis, and Survival Support Vector Machine (SurvSVM). Cox regression is a non-parametric method commonly used in survival analysis, suitable for various data types and distributions [<xref ref-type="bibr" rid="CR37">37</xref>]. The XGBoost algorithm minimizes a loss function to learn weak classifiers and then combines them into a strong classifier to improve accuracy and generalization [<xref ref-type="bibr" rid="CR38">38</xref>]. SVM is a supervised learning algorithm that finds the optimal hyperplane by maximizing the margin, thus classifying and performing regression analysis on data points [<xref ref-type="bibr" rid="CR39">39</xref>]. The XGBoost survival analysis model and SurvSVM model integrate machine learning classification and regression capabilities with survival analysis methods, effectively handling right-censored survival data [<xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>].</p><sec id="Sec9"><title>Development of the Cox model</title><p id="Par20">Using a multivariate Cox proportional hazards regression approach, with extensive metastasis as the dependent variable and EFS as the time variable, all risk factors were incorporated into the model development in the training cohort. Based on the risk coefficients and clinical parameters, linear predictions (Prognosis Index, PI) were calculated for each patient in the training, testing, and ALL cohorts, and this value was used as the Cox Regression Risk Score (COXRiskScore, CRS). The median CRS for each cohort was used as the cutoff point to classify patients into high-risk and low-risk groups across the three cohorts.</p></sec><sec id="Sec10"><title>Development of the XGBoost model</title><p id="Par21">For the XGBoost model, hyperparameter tuning was initially performed to select parameters including the number of iterations (nrounds), feature column ratio (colsample_bytree), minimum child weight (min_child_weight), learning rate (eta), minimum loss reduction required for a split (gamma), sample ratio (subsample), and maximum depth of the tree (max_depth). The tuning process was evaluated using tenfold cross-validation to ensure the model&#x02019;s robustness and generalizability. After determining the optimal hyperparameter configuration, the XGBoost model was fitted on the training cohort, with early stopping rounds (early_stopping_rounds) set to prevent overfitting and enhance model efficiency. The gain for each split node was calculated to assess the contribution of the selected features, and a variable importance plot was created to visually display the significance of each risk factor in the XGBoost model. Similarly, risk scores (XGBoostRiskScore, XGBRS) for the XGBoost model were calculated for patients in the training, testing, and ALL cohorts. The median XGBRS for each cohort was used as the cutoff point to classify patients into high-risk and low-risk groups across the three cohorts.</p></sec><sec id="Sec11"><title>Development of the SurvSVM model</title><p id="Par22">A SurvSVM model for survival analysis was developed using regression methods to predict EFS and outcome status, a technique referred to as SVCR in VanBelle et al.&#x02019;s literature [<xref ref-type="bibr" rid="CR42">42</xref>]. The model regularization parameter was set to 1, with an additive kernel function selected, and the quadprog solver was used to solve the quadratic optimization problem derived from the model&#x02019;s support vector formulation to determine the optimal classification hyperplane or regression function. The SurvSVM model incorporated all risk factors and was fitted on the training cohort. The predicted risk ranks for patients in the training, testing, and ALL cohorts were calculated. In the SurvSVM model, a higher predicted risk rank corresponds to a longer survival time, so the predicted risk ranks were used as the SurvSVM Risk Score (SVMRS) in subsequent analyses. The SVMRS was calculated for the training, testing, and ALL cohorts. The median SVMRS for each cohort was used as the cutoff point to classify patients into high-risk and low-risk groups across the three cohorts.</p></sec></sec><sec id="Sec12"><title>Testing, evaluation, and visualization of predictive models</title><p id="Par23">Model validation and evaluation were conducted in the training cohort, testing cohort, and ALL cohort. The models&#x02019; discriminative ability was assessed using the C-index and the AUC curve to evaluate their ability to distinguish between different risk groups [<xref ref-type="bibr" rid="CR43">43</xref>]. Calibration curves were used to assess the models&#x02019; calibration, ensuring the consistency between predicted probabilities and observed outcomes [<xref ref-type="bibr" rid="CR44">44</xref>]. KM curves were plotted to evaluate the models&#x02019; event prediction and risk stratification capabilities across different datasets. After evaluating the overall performance of the three models across the three cohorts, the optimal model was selected for DCA. The DCA curves were used to assess the net benefit of clinical decisions based on the model [<xref ref-type="bibr" rid="CR45">45</xref>], and a nomogram was employed to visually represent the best model [<xref ref-type="bibr" rid="CR46">46</xref>].</p></sec><sec id="Sec13"><title>Statistical analysis</title><p id="Par24">All statistical analyses in this study were performed using R version 4.3.1, employing packages such as &#x0201c;glmnet,&#x0201d; &#x0201c;survival,&#x0201d; &#x0201c;xgboost,&#x0201d; &#x0201c;survivalsvm,&#x0201d; and &#x0201c;rms&#x0201d; [<xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR53">53</xref>]. Continuous data following a normal distribution were described as mean&#x02009;&#x000b1;&#x02009;standard deviation, and comparisons between two groups were made using the Student&#x02019;s <italic>t</italic>-test. For continuous data not following a normal distribution, data were described as median (interquartile range), and the Wilcoxon rank-sum test was used for comparisons between two groups. Categorical data were described as frequency (percentage) and analyzed using the chi-square test for comparisons between two groups. If the expected frequency of categorical data was too small to meet the chi-square test conditions, Fisher&#x02019;s exact test was used. A two-sided <italic>p</italic>-value of&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant unless otherwise specified.</p></sec></sec><sec id="Sec14"><title>Results</title><sec id="Sec15"><title>The characteristics of patients</title><p id="Par25">Table <xref rid="Tab1" ref-type="table">1</xref> presents the basic characteristics of the patients and their distribution in the training, testing, and ALL cohort. The proportion of patients with extensive metastasis is higher in the training and ALL cohorts compared to the testing cohort. In the testing cohort, the number of patients with extensive metastasis is equal to the number of patients without. The median EFS is similar across the three cohorts, with the training cohort having an EFS of 25&#x000a0;months and both the testing and ALL cohort having an EFS of 26&#x000a0;months. Most patients in the three cohorts are in clinical stage IV and T stage IV, with moderately to well-differentiated adenocarcinoma being the predominant HT. The proportion of male patients is higher than that of female patients. Further inter-cohort comparisons revealed no statistically significant differences between the cohorts (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, <italic>p</italic>&#x02009;&#x02265;&#x02009;0.05).
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Clinical information in training, testing, and ALL cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Training cohort</th><th align="left">Testing cohort</th><th align="left">ALL cohort</th><th align="left">Methods for inter-group comparison</th><th align="left"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left">Total</td><td align="left">136</td><td align="left">78</td><td align="left">214</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Outcome</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Chisq. (2 <italic>df</italic>)&#x02009;=&#x02009;0.39</td><td char="." align="char">0.824</td></tr><tr><td align="left">&#x000a0; Non-extensive metastasis</td><td align="left">62 (45.6)</td><td align="left">39 (50)</td><td align="left">101 (47.2)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0; Extensive metastasis</td><td align="left">74 (54.4)</td><td align="left">39 (50)</td><td align="left">113 (52.8)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">EFS</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Kruskal&#x02013;Wallis test</td><td char="." align="char">0.955</td></tr><tr><td align="left">&#x000a0; Median (IQR)</td><td align="left">25 (14, 38.2)</td><td align="left">26 (15, 39)</td><td align="left">26 (14.2, 39)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Gender</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Chisq. (2 <italic>df</italic>)&#x02009;=&#x02009;0.61</td><td char="." align="char">0.736</td></tr><tr><td align="left">&#x000a0; &#x000a0; Male</td><td align="left">78 (57.4)</td><td align="left">49 (62.8)</td><td align="left">127 (59.3)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0; &#x000a0; Female</td><td align="left">58 (42.6)</td><td align="left">29 (37.2)</td><td align="left">87 (40.7)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Clinical_stage</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Chisq. (4 <italic>df</italic>)&#x02009;=&#x02009;1.09</td><td char="." align="char">0.895</td></tr><tr><td align="left">&#x000a0; &#x000a0; 1&#x02009;+&#x02009;2</td><td align="left">28 (20.6)</td><td align="left">12 (15.4)</td><td align="left">40 (18.7)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0; &#x000a0; 3</td><td align="left">38 (27.9)</td><td align="left">21 (26.9)</td><td align="left">59 (27.6)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0; &#x000a0; 4</td><td align="left">70 (51.5)</td><td align="left">45 (57.7)</td><td align="left">115 (53.7)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">T_stage</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Chisq. (4 <italic>df</italic>)&#x02009;=&#x02009;3.47</td><td char="." align="char">0.482</td></tr><tr><td align="left">&#x000a0; &#x000a0;1&#x02009;+&#x02009;2</td><td align="left">10 (7.4)</td><td align="left">12 (15.4)</td><td align="left">22 (10.3)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0; &#x000a0;3</td><td align="left">56 (41.2)</td><td align="left">29 (37.2)</td><td align="left">85 (39.7)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0; &#x000a0;4</td><td align="left">70 (51.5)</td><td align="left">37 (47.4)</td><td align="left">107 (50)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">OE</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Chisq. (6 <italic>df</italic>)&#x02009;=&#x02009;3.59</td><td char="." align="char">0.732</td></tr><tr><td align="left">&#x000a0; &#x000a0;Intestinal metastasis</td><td align="left">15 (11)</td><td align="left">3 (3.8)</td><td align="left">18 (8.4)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0; &#x000a0;Hepatic metastasis</td><td align="left">84 (61.8)</td><td align="left">53 (67.9)</td><td align="left">137 (64)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0; &#x000a0;Pulmonary metastasis</td><td align="left">32 (23.5)</td><td align="left">18 (23.1)</td><td align="left">50 (23.4)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0; &#x000a0;Metastasis of other organs</td><td align="left">5 (3.7)</td><td align="left">4 (5.1)</td><td align="left">9 (4.2)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">WST</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Chisq. (2 <italic>df</italic>)&#x02009;=&#x02009;0</td><td char="." align="char">0.999</td></tr><tr><td align="left">&#x000a0; &#x000a0;Non-surgical treatment</td><td align="left">78 (57.4)</td><td align="left">45 (57.7)</td><td align="left">123 (57.5)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0; &#x000a0;Surgical treatment</td><td align="left">58 (42.6)</td><td align="left">33 (42.3)</td><td align="left">91 (42.5)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">NCN</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Chisq. (2 <italic>df</italic>)&#x02009;=&#x02009;5.25</td><td char="." align="char">0.073</td></tr><tr><td align="left">&#x000a0; &#x000a0;No cancer nodules detected</td><td align="left">94 (69.1)</td><td align="left">65 (83.3)</td><td align="left">159 (74.3)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0; &#x000a0;Detected cancer nodules</td><td align="left">42 (30.9)</td><td align="left">13 (16.7)</td><td align="left">55 (25.7)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">HT</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Chisq. (2 <italic>df</italic>)&#x02009;=&#x02009;0.28</td><td char="." align="char">0.868</td></tr><tr><td align="left">&#x000a0; &#x000a0;Poorly differentiated adenocarcinoma</td><td align="left">19 (14)</td><td align="left">13 (16.7)</td><td align="left">32 (15)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0; &#x000a0;Moderately to well-differentiated adenocarcinoma</td><td align="left">117 (86)</td><td align="left">65 (83.3)</td><td align="left">182 (85)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">NPLN</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Kruskal&#x02013;Wallis test</td><td char="." align="char">0.122</td></tr><tr><td align="left">&#x000a0; &#x000a0;Median (IQR)</td><td align="left">1 (0, 2)</td><td align="left">1 (0, 3.8)</td><td align="left">1 (0, 3)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Preop_PLR</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Kruskal&#x02013;Wallis test</td><td char="." align="char">0.527</td></tr><tr><td align="left">&#x000a0; &#x000a0;Median (IQR)</td><td align="left">4.4 (4, 4.9)</td><td align="left">4.3 (3.9, 4.9)</td><td align="left">4.4 (4, 4.9)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Preop_LA</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Kruskal&#x02013;Wallis test</td><td char="." align="char">0.750</td></tr><tr><td align="left">&#x000a0; Median (IQR)</td><td align="left">4.6 (4, 5.2)</td><td align="left">4.8 (4.2, 5.4)</td><td align="left">4.7 (4.1, 5.3)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Preop_AGR</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Kruskal&#x02013;Wallis test</td><td char="." align="char">0.973</td></tr><tr><td align="left">&#x000a0; &#x000a0;Median (IQR)</td><td align="left">1.1 (1, 1.2)</td><td align="left">1.1 (1.1, 1.2)</td><td align="left">1.1 (1, 1.2)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Postop_CEA</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Kruskal&#x02013;Wallis test</td><td char="." align="char">1.000</td></tr><tr><td align="left">&#x000a0; &#x000a0;Median (IQR)</td><td align="left">1.6 (1.1,2.7)</td><td align="left">1.5 (1.1,2.6)</td><td align="left">1.6 (1.1,2.7)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">CEA_after_1st_Postop_Tx</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Kruskal&#x02013;Wallis test</td><td char="." align="char">0.360</td></tr><tr><td align="left">&#x000a0; &#x000a0;Median (IQR)</td><td align="left">1.6 (1.3, 3.1)</td><td align="left">1.8 (1.4, 3.7)</td><td align="left">1.7 (1.3, 3.2)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">CA199_after_1st_Postop_Tx</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Kruskal&#x02013;Wallis test</td><td char="." align="char">0.864</td></tr><tr><td align="left">&#x000a0; &#x000a0;Median (IQR)</td><td align="left">3 (2.2, 4)</td><td align="left">2.9 (2.4, 4.1)</td><td align="left">3 (2.2, 4)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">CEA_at_Oligo</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Kruskal&#x02013;Wallis test</td><td char="." align="char">0.881</td></tr><tr><td align="left">&#x000a0; &#x000a0;Median (IQR)</td><td align="left">2.2 (1.6, 3.9)</td><td align="left">2.2 (1.7, 3.5)</td><td align="left">2.2 (1.6, 3.6)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">CEA_after_Oligo_Tx</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Kruskal&#x02013;Wallis test</td><td char="." align="char">0.840</td></tr><tr><td align="left">&#x000a0; &#x000a0;Median (IQR)</td><td align="left">1.7 (1.4, 2.8)</td><td align="left">1.8 (1.3, 2.5)</td><td align="left">1.7 (1.4, 2.6)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">CA50_at_LFU</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Kruskal&#x02013;Wallis test</td><td char="." align="char">0.980</td></tr><tr><td align="left">&#x000a0; &#x000a0;Median (IQR)</td><td align="left">3.1 (1.8,5)</td><td align="left">3.3 (2.1, 4.6)</td><td align="left">3.2 (1.9, 4.6)</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">CEA_at_LFU</td><td align="left"/><td align="left"/><td align="left"/><td align="left">Kruskal&#x02013;Wallis test</td><td char="." align="char">1.000</td></tr><tr><td align="left">&#x000a0; &#x000a0;Median (IQR)</td><td align="left">2.5 (1.6, 4.5)</td><td align="left">2.4 (1.7, 4.4)</td><td align="left">2.5 (1.6, 4.5)</td><td align="left"/><td char="." align="char"/></tr></tbody></table><table-wrap-foot><p><italic>IQR&#x000a0;</italic>interquartile range</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec16"><title>Selection of risk factors</title><sec id="Sec17"><title>LASSO regression analysis</title><p id="Par26">A total of 71 candidate variables were included in this study, and the LASSO regression model was fitted using data from all patients (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). Through tenfold cross-validation, the minimum lambda value (lambda min) was 0.061, corresponding to 20 non-zero coefficients; the minimum lambda minus standard error (lambda min-se) was 0.246, corresponding to 0 non-zero coefficients (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b). A total of 18 candidate variables were identified for subsequent analysis, including gender, clinical stage, T stage, OE, WST, NCN, HT, NPLN, preoperative CEA (Postop-CEA), CEA after the first postoperative treatment (CEA after 1st Postop-Tx), CA199 after the first postoperative treatment (CA199 after 1st Postop-Tx), CEA at the time of oligometastasis (CEA at Oligo), CEA after oligometastasis treatment (CEA after Oligo-Tx), CA50 at last follow-up (CA50 at LFU), CEA at LFU, preoperative PLR (Preop-PLR), preoperative LA (Preop-LA), and Preop-AGR.<fig id="Fig2"><label>Fig. 2</label><caption><p>LASSO regression analysis and cross-validation (*80 parameters were included in the LASSO regression due to dummy variable settings)</p></caption><graphic xlink:href="384_2025_4841_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec18"><title>COX proportional hazards regression analysis</title><p id="Par27">Univariate Cox proportional hazards regression analysis was performed on 18 candidate variables. Based on the selection criteria (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 or HR&#x02009;&#x0003e;&#x02009;1.3 or HR&#x02009;&#x0003c;&#x02009;0.7), 17 of the 18 candidate variables, excluding gender, were identified as potential risk factors for EFS (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Subsequently, these 17 potential risk factors were included in a multivariate Cox proportional hazards regression analysis. The proportional hazards assumption test (Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">3</xref>) and the Schoenfeld residual plot (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>) indicated that all variables met the proportional hazards assumption (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05), and the global significance test confirmed good model fit (GLOBAL <italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05). The multivariate Cox proportional hazards regression analysis (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>) identified 4 independent risk factors associated with EFS (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 and HR&#x02009;&#x0003e;&#x02009;1.1 or HR&#x02009;&#x0003c;&#x02009;0.9): WST (surgical treatment vs non-surgical treatment: HR&#x02009;=&#x02009;0.52, <italic>P</italic>&#x02009;=&#x02009;0.003); HT (moderately to well-differentiated adenocarcinoma vs poorly differentiated adenocarcinoma: HR&#x02009;=&#x02009;0.41, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001); CEA at LFU (HR&#x02009;=&#x02009;1.15, <italic>P</italic>&#x02009;=&#x02009;0.031); and Preop-AGR (HR&#x02009;=&#x02009;0.05, <italic>P</italic>&#x02009;=&#x02009;0.023). The global significance test of the multivariate Cox proportional hazards regression analysis had a <italic>P</italic> value of&#x02009;&#x0003c;&#x02009;0.001, indicating that these 4 independent risk factors have predictive value for patients&#x02019; EFS.<fig id="Fig3"><label>Fig. 3</label><caption><p>Forest plot of univariate and multivariate Cox proportional hazards regression analyses</p></caption><graphic xlink:href="384_2025_4841_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec19"><title>Validation of risk factors</title><p id="Par28">KM curves were plotted for the four independent risk factors (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a&#x02013;d) and the thirteen potential risk factors (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2</xref>a-m) in relation to EFS, stratified by the median if the risk factor was continuous. The KM curves for WST, HT, and CEA at LFU showed clear separation throughout, with statistically significant differences (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05), indicating strong independent risk stratification capability. Despite crossing at 0&#x02013;13&#x000a0;months and after 91&#x000a0;months, the KM curve for Preop-AGR showed overall good separation with statistical significance, also demonstrating good independent risk stratification capability (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). Among the 13 potential risk factors, CEA after 1st Postop-Tx, CEA at Oligo, CEA after Oligo-Tx, and CA50 at LFU also showed some risk stratification capability. Although the curves for T stage and OE showed statistically significant differences (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) and trends consistent with Cox proportional hazards regression analysis, there was crossing within the variable groups. The KM curves for NCN, Postop-CEA, and CA199 after 1st Postop-Tx showed good separation but lacked statistical significance (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05), suggesting limited risk stratification capability. The remaining potential risk factors (clinical stage, NPLN, Preop-PLR, Preop-LA) showed poor separation, with no statistically significant differences, indicating poor independent risk stratification capability.<fig id="Fig4"><label>Fig. 4</label><caption><p><bold> a</bold> KM curve of patients grouped by WST; <bold>b</bold> KM curve of patients grouped by HT; <bold>c</bold> KM curve of patients grouped by median CEA at LFU; <bold>d</bold> KM curve of patients grouped by median Preop-AGR</p></caption><graphic xlink:href="384_2025_4841_Fig4_HTML" id="MO4"/></fig></p></sec></sec><sec id="Sec20"><title>Model evaluation</title><sec id="Sec21"><title>Assessment and comparison of discrimination</title><p id="Par29">All three models achieved an AUC greater than 0.8 in the training cohort, indicating good discriminatory power (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a&#x02013;c). Among them, the XGBoost model performed best in the training set (1-year AUC&#x02009;=&#x02009;0.83, 3-year AUC&#x02009;=&#x02009;0.96, 5-year AUC&#x02009;=&#x02009;0.97, mean AUC&#x02009;=&#x02009;0.92). The COX model (1-year AUC&#x02009;=&#x02009;0.83, 3-year AUC&#x02009;=&#x02009;0.83, 5-year AUC&#x02009;=&#x02009;0.85, mean AUC&#x02009;=&#x02009;0.84) and the SurvSVM model (1-year AUC&#x02009;=&#x02009;0.82, 3-year AUC&#x02009;=&#x02009;0.83, 5-year AUC&#x02009;=&#x02009;0.85, mean AUC&#x02009;=&#x02009;0.83) showed similar performance. The mean AUC of the three prediction models in the testing cohort and the ALL cohort were both greater than 0.7 (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3</xref>a-f), indicating good discriminatory power in the ALL cohort and the unfamiliar testing cohort. This consistent performance demonstrates the models&#x02019; robustness and generalizability, verifying their reliability in real-world scenarios. In the testing cohort, the COX model (1-year AUC&#x02009;=&#x02009;0.82, 3-year AUC&#x02009;=&#x02009;0.72, 5-year AUC&#x02009;=&#x02009;0.85, mean AUC&#x02009;=&#x02009;0.80) performed best. Although the SurvSVM model had a 3-year AUC&#x02009;&#x0003c;&#x02009;0.70 in the testing cohort (1-year AUC&#x02009;=&#x02009;0.76, 3-year AUC&#x02009;=&#x02009;0.63, 5-year AUC&#x02009;=&#x02009;0.87, mean AUC&#x02009;=&#x02009;0.75), its mean AUC was still better than the XGBoost model (1-year AUC&#x02009;=&#x02009;0.75, 3-year AUC&#x02009;=&#x02009;0.73, 5-year AUC&#x02009;=&#x02009;0.70, mean AUC&#x02009;=&#x02009;0.73). In the ALL cohort, the SurvSVM model (1-year AUC&#x02009;=&#x02009;0.80, 3-year AUC&#x02009;=&#x02009;0.76, 5-year AUC&#x02009;=&#x02009;0.87, mean AUC&#x02009;=&#x02009;0.81) and the COX model (1-year AUC&#x02009;=&#x02009;0.82, 3-year AUC&#x02009;=&#x02009;0.79, 5-year AUC&#x02009;=&#x02009;0.86, mean AUC&#x02009;=&#x02009;0.82) had similar performance, with the XGBoost model performing best (1-year AUC&#x02009;=&#x02009;0.81, 3-year AUC&#x02009;=&#x02009;0.88, 5-year AUC&#x02009;=&#x02009;0.89, mean AUC&#x02009;=&#x02009;0.86).<fig id="Fig5"><label>Fig. 5</label><caption><p><bold> a</bold> ROC curves for the COX model at 1, 3, and 5&#x000a0;years in the training cohort; <bold>b</bold> ROC curves for the XGBoost model at 1, 3, and 5&#x000a0;years in the training cohort; <bold>c</bold> ROC curves for the SurvSVM model at 1, 3, and 5&#x000a0;years in the training cohort</p></caption><graphic xlink:href="384_2025_4841_Fig5_HTML" id="MO5"/></fig></p><p id="Par30">The COX model exhibited a C-index greater than 0.7 in the training, testing, and ALL cohorts, consistent with the ROC curve evaluations (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, training cohort C-index&#x02009;=&#x02009;0.756, testing cohort C-index&#x02009;=&#x02009;0.724, ALL cohort C-index&#x02009;=&#x02009;0.744, mean C-index&#x02009;=&#x02009;0.741). Both the SurvSVM and XGBoost models had C-index values below 0.7 in the testing cohort, but the SurvSVM model (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, training cohort C-index&#x02009;=&#x02009;0.747, testing cohort C-index&#x02009;=&#x02009;0.670, ALL cohort C-index&#x02009;=&#x02009;0.719, mean C-index&#x02009;=&#x02009;0.712) demonstrated superior overall performance across the three datasets compared to the XGBoost model (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, training cohort C-index&#x02009;=&#x02009;0.731, testing cohort C-index&#x02009;=&#x02009;0.612, ALL cohort C-index&#x02009;=&#x02009;0.688, mean C-index&#x02009;=&#x02009;0.677).
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>C-index of three models in training, testing, and ALL cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">COX model</th><th align="left">XGBoost model</th><th align="left">SurvSVM model</th></tr></thead><tbody><tr><td align="left">Training cohort</td><td char="." align="char">0.756</td><td char="." align="char">0.731</td><td char="." align="char">0.747</td></tr><tr><td align="left">Testing cohort</td><td char="." align="char">0.724</td><td char="." align="char">0.612</td><td char="." align="char">0.670</td></tr><tr><td align="left">ALL cohort</td><td char="." align="char">0.744</td><td char="." align="char">0.688</td><td char="." align="char">0.719</td></tr><tr><td align="left">Mean</td><td char="." align="char">0.741</td><td char="." align="char">0.677</td><td char="." align="char">0.712</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec22"><title>Assessment and comparison of calibration</title><p id="Par31">In the training cohort, the 1-year and 5-year calibration curves of the COX model closely aligned with the 45-degree line, indicating good agreement between observed and predicted risks across the entire range of predicted risks (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a). However, the model showed some miscalibration in the 3-year calibration curve; it slightly understimated risk when the predicted risk was between 0.3 and 0.7 and slightly overestimated risk when the predicted risk was between 0.1 and 0.2 (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a). In the testing cohort, the model showed slight miscalibration of observed risk at 1&#x000a0;year (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>b). The 3-year and 5-year calibration curves in the testing cohort suggested slight underestimation of risk by the model (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>b). In the ALL cohort, the model slightly underestimated the observed risk at 3&#x000a0;years (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>c). The 1-year and 5-year calibration curves for the entire cohort indicate good model calibration (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>c).<fig id="Fig6"><label>Fig. 6</label><caption><p><bold> a</bold> Calibration curves at 1, 3, and 5&#x000a0;years for the COX model in the training cohort; <bold>b</bold> calibration curves at 1, 3, and 5&#x000a0;years for the COX model in the testing cohort; <bold>c</bold> calibration curves at 1, 3, and 5&#x000a0;years for the COX model in the ALL cohort; <bold>d</bold> calibration curves at 1, 3, and 5&#x000a0;years for the XGBoost model in the training cohort; <bold>e</bold> calibration curves at 1, 3, and 5&#x000a0;years for the XGBoost model in the testing cohort; <bold>f</bold> calibration curves at 1, 3, and 5&#x000a0;years for the XGBoost model in the ALL cohort; <bold>g</bold> calibration curves at 1, 3, and 5&#x000a0;years for the SurvSVM model in the training cohort; <bold>h</bold> calibration curves at 1, 3, and 5&#x000a0;years for the SurvSVM model in the testing cohort; <bold>i</bold> calibration curves at 1, 3, and 5&#x000a0;years for the SurvSVM model in the ALL cohort</p></caption><graphic xlink:href="384_2025_4841_Fig6_HTML" id="MO6"/></fig></p><p id="Par32">In the training cohort, the 1-year calibration curve of the XGBoost model showed some overestimation of risk (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>d). Additionally, the model&#x02019;s 3-year and 5-year calibration curves in the training cohort performed poorly. At the 3-year mark, the model underestimated risk for high-risk patients (predicted risk&#x02009;&#x0003e;&#x02009;0.5) and overestimated risk for low-risk patients (predicted risk&#x02009;&#x0003c;&#x02009;0.5). By the 5-year mark, the model underrestimated risk for patients with predicted risk&#x02009;&#x0003e;&#x02009;0.35 and overestimated risk for those with predicted risk&#x02009;&#x0003c;&#x02009;0.35 (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>d). The XGBoost model exhibited similar patterns in the ALL cohort, with poor 3-year and 5-year calibration curves (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6f</xref>). In the testing cohort, the model performed poorly across most regions for 1-year, 3-year, and 5-year predicted risks (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>e), showing mixed overestimation and underestimation of risks. These results indicate that the XGBoost survival analysis model has poor calibration, especially when predicting unfamiliar data, and its performance deteriorates over time.</p><p id="Par33">The SurvSVM model&#x02019;s 1-year calibration curve in the training cohort closely aligned with the 45-degree line, indicating good agreement between observed and predicted risks across the entire range of predicted risks (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>g). The 3-year and 5-year calibration curves in the training cohort showed slight miscalibration. At 3&#x000a0;years, the model slightly underestimated risk when the predicted risk was&#x02009;&#x0003e;&#x02009;0.6 and slightly overestimated risk when the predicted risk was&#x02009;&#x0003c;&#x02009;0.6 (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>g). In the ALL cohort, the SurvSVM model&#x02019;s 3-year calibration curve showed good alignment between observed and predicted risks across the entire range (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>i). However, the 1-year and 5-year calibration curves exhibited mixed overestimation and underestimation of risks. In the testing cohort, the SurvSVM model showed poor calibration across most areas for 1-year, 3-year, and 5-year predicted risks, with mixed overestimation and underestimation of risks across the entire risk spectrum (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>h).</p><p id="Par34">The KM curves for the COX model, XGBoost model, and SurvSVM model in the training cohort, testing cohort, and ALL cohort all showed significant separation, with corresponding <italic>P-</italic>values indicating statistical significance (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4</xref>a-i, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). This suggests that all three models have good predictive and discriminatory power, effectively distinguishing between individuals with different risk levels across various cohorts.</p></sec></sec><sec id="Sec23"><title>Decision curve analysis</title><p id="Par35">The COX model maintained consistent discriminatory power while also demonstrating a certain level of calibration across all cohorts. Therefore, it was selected as the optimal model for decision curve analysis, and a DCA curve was plotted (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>). The 1-year and 5-year DCA curves for the COX model are above the horizontal line None and the diagonal line ALL. The 3-year DCA curve intersects with the diagonal line ALL when the threshold is between 0.125 and 0.25, but at other threshold values, the 3-year DCA curve remains above the horizontal line None and the diagonal line ALL. Overall, although the net benefit of clinical decision-making based on the model predictions decreases with increasing thresholds, there is almost always a net benefit across the full range of thresholds when making clinical decisions based on the COX model&#x02019;s predictions.<fig id="Fig7"><label>Fig. 7</label><caption><p>1-year, 3-year, and 5-year DCA curves for the COX model</p></caption><graphic xlink:href="384_2025_4841_Fig7_HTML" id="MO7"/></fig></p></sec><sec id="Sec24"><title>Model visualization</title><p id="Par36">In the training cohort, nomograms were constructed using the COX method. Based on patients&#x02019; EFS and outcome status, four patients from the testing cohort were selected in natural order for the nomogram display. Patient A had an EFS of 3&#x000a0;months and developed extensive metastases; patient B had an EFS of 26&#x000a0;months and developed extensive metastases; patient C had an EFS of 43&#x000a0;months and developed extensive metastases; patient D had an EFS of 72&#x000a0;months and was censored. The total score for patient A&#x02019;s nomogram was 752, predicting a 1-year EFS probability of 0.609 and probabilities of less than 0.01 for 3-year and 5-year EFS (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>a). The total score for patient B&#x02019;s nomogram was 698, predicting a 1-year EFS probability of 0.871, a 3-year probability of 0.283, and a 5-year probability of 0.109 (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>b). The total score for patient C&#x02019;s nomogram was 662, predicting a 1-year EFS probability of 0.944, a 3-year probability of 0.588, and a 5-year probability of 0.394 (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>c). The total score for patient D&#x02019;s nomogram was 588, predicting a 1-year EFS probability of 0.99, a 3-year probability of 0.914, and a 5-year probability of 0.853 (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>d). This demonstrates that even in the unfamiliar testing cohort, the nomogram based on the COX model can quickly and accurately predict patient outcomes at various risk levels.<fig id="Fig8"><label>Fig. 8</label><caption><p><bold> a</bold> 1-year, 3-year, and 5-year EFS for patient A; <bold>b</bold> 1-year, 3-year, and 5-year EFS for patient B; <bold>c</bold> 1-year, 3-year, and 5-year EFS for patient C; <bold>d</bold> 1-year, 3-year, and 5-year EFS for patient D</p></caption><graphic xlink:href="384_2025_4841_Fig8_HTML" id="MO8"/></fig></p></sec></sec><sec id="Sec25"><title>Discussion</title><p id="Par37">CRC is a globally prevalent cancer with a high incidence and mortality rate. Approximately half of CRC patients experienced tumor metastasis during their lifetime, with the liver and lungs being the most common sites of metastasis [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. OMCRC is a specific subtype of CRC where local treatment of metastatic lesions combined with systemic therapy can significantly improve patient prognosis. As the disease progresses, patients with OMCRC may still develop extensive metastases, severely impacting prognosis [<xref ref-type="bibr" rid="CR8">8</xref>]. Thus, there is an urgent need for personalized treatment and follow-up plans for patients with OMCRC. The study conducted a retrospective analysis of survival data and clinical information from patients with OMCRC to identify clinical risk factors leading to extensive metastasis and developed three clinical prediction models. Although all models demonstrated good discriminatory ability, comprehensive performance evaluation revealed that in low-latitude clinical settings, COX proportional hazards regression analysis may offer good discrimination and reasonable calibration.</p><p id="Par38">Research on OMCRC is still in its infancy. In the study, clinical risk factors associated with CRC recurrence and metastasis were selected based on clinical guidelines and literatures as candidates. Gender and age were included as basic patient information, as previous studies have highlighted their predictive value for CRC metastasis [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. In terms of tumor pathology data, TNM staging, clinical stage, HT, NCN, NCN, and WVI or WNI have been widely used in various tumor metastasis risk prediction models [<xref ref-type="bibr" rid="CR58">58</xref>&#x02013;<xref ref-type="bibr" rid="CR60">60</xref>]. Additionally, tumor metastasis sites, synchronous metastasis, and subsequent treatment plans are also associated with local recurrence of CRC [<xref ref-type="bibr" rid="CR61">61</xref>&#x02013;<xref ref-type="bibr" rid="CR64">64</xref>]. Furthermore, this study included various tumor markers such as CEA and CA199. CEA is frequently considered in CRC research, with elevated levels linked to increased incidence of CRC [<xref ref-type="bibr" rid="CR65">65</xref>]. Studies have shown that elevated Preop-CEA levels are associated with higher rates of CRC recurrence and liver metastasis [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. CA199 has also been confirmed to have prognostic value for gastrointestinal tumors [<xref ref-type="bibr" rid="CR68">68</xref>]. Inflammation, particularly chronic inflammation, is considered a significant risk factor for cancer development. Inflammatory markers such as PLR, LMR, PNI, and CRP are closely related to CRC prognosis [<xref ref-type="bibr" rid="CR69">69</xref>&#x02013;<xref ref-type="bibr" rid="CR72">72</xref>]. However, existing research often relies on static data from specific time points and overlooks the dynamic nature of tumor progression. Time series analysis has gained attention from researchers, with some studies making progress in analyzing dynamic tumor evolution through time series data [<xref ref-type="bibr" rid="CR73">73</xref>&#x02013;<xref ref-type="bibr" rid="CR76">76</xref>]. Therefore, to more accurately predict the risk of extensive metastasis in OMCRC, we included hematological data from several key time points during patient follow-up as candidate factors. Subsequent analysis confirmed that the time series behavior of CEA has predictive value for the risk of extensive metastasis in OMCRC.</p><p id="Par39">This study employed LASSO regression analysis for feature selection, minimizing the impact of multicollinearity on subsequent regression analyses [<xref ref-type="bibr" rid="CR34">34</xref>]. Variables selected through LASSO regression underwent univariate COX proportional hazards regression analysis to examine their relationship with EFS. Statistical indicators and clinical relevance were used as screening criteria to assess the association between risk factors and EFS, a method widely applied in medical research [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]. Ultimately, multivariate COX proportional hazards regression analysis identified 4 independent risk factors and 13 potential risk factors for extensive metastasis in patients with OMCRC. The four independent risk factors provided distinct predictive value for the risk of extensive metastasis, while the potential risk factors offered supplementary value when combined with the independent risk factors in assessing the risk of extensive metastasis. Tumor HT has been found to correlate closely with patient prognosis in various cancers [<xref ref-type="bibr" rid="CR79">79</xref>]. In CRC, poorly differentiated adenocarcinoma is associated with an increased risk of liver metastasis, and patients with poorly differentiated adenocarcinoma often have a lower overall survival rate compared to those with well-differentiated adenocarcinoma [<xref ref-type="bibr" rid="CR80">80</xref>]. Similarly, this study found that patients with poorly differentiated adenocarcinoma had a higher risk of extensive metastasis compared to those with moderately to well-differentiated adenocarcinoma (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, moderately to well-differentiated adenocarcinoma vs poorly differentiated adenocarcinoma: HR&#x02009;=&#x02009;0.41, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). CEA is one of the most commonly used tumor markers for assessing CRC, closely related to patient prognosis. Previous research has identified Preop-CEA levels greater than 200 as a significant predictor of CRC recurrence risk [<xref ref-type="bibr" rid="CR81">81</xref>]. Although this study did not find Preop-CEA to be predictive of the risk of extensive metastasis in OMCRC, Postop-CEA (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, HR&#x02009;=&#x02009;1.09, <italic>P</italic>&#x02009;=&#x02009;0.175), CEA after 1st Postop-Tx (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, HR&#x02009;=&#x02009;1.07, <italic>P</italic>&#x02009;=&#x02009;0.358), CEA at Oligo (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, HR&#x02009;=&#x02009;1.01, <italic>P</italic>&#x02009;=&#x02009;0.917), and CEA after Oligo-Tx (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, HR&#x02009;=&#x02009;1.11, <italic>P</italic>&#x02009;=&#x02009;0.267) demonstrated potential value in assessing the risk of extensive metastasis. Furthermore, elevated CEA during follow-up in patients with OMCRC was associated with an increased risk of extensive metastasis (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, HR&#x02009;=&#x02009;1.15, <italic>P</italic>&#x02009;=&#x02009;0.031). AGR, a combination of nutritional and inflammatory markers, is commonly used to assess immune nutrition and inflammatory status. Previous studies have found AGR to be closely related to prognosis in various cancers, including CRC, gastric, and breast cancers [<xref ref-type="bibr" rid="CR82">82</xref>&#x02013;<xref ref-type="bibr" rid="CR85">85</xref>]. Consistent with previous research, this study found that high AGR status before curative surgery for CRC was associated with a lower risk of extensive metastasis after oligometastasis (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, HR&#x02009;=&#x02009;0.05, <italic>P</italic>&#x02009;=&#x02009;0.023). Curative surgery remains the preferred treatment for CRC patients. For those with resectable liver metastases, surgical resection of metastatic lesions remains the only potential curative option [<xref ref-type="bibr" rid="CR86">86</xref>]. Retrospective studies on metastatic CRC patients undergoing multiple lines of treatment suggest that surgery for metastatic lesions is an important prognostic factor [<xref ref-type="bibr" rid="CR87">87</xref>]. Similarly, this study found that surgery for metastatic lesions was associated with a reduced risk of extensive metastasis in patients with OMCRC (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, HR&#x02009;=&#x02009;0.52, <italic>P</italic>&#x02009;=&#x02009;0.003).</p><p id="Par40">The study has certain limitations. (1) While the study suggests that factors such as WST, HT, CEA at LFU, and Preop-AGR are associated with the risk of extensive metastasis in patients with OMCRC, it cannot establish causal relationships between these risk factors and the risk of extensive metastasis. (2) In this study, we did not consider genomic data. Genomic data is crucial for understanding the occurrence, progression, and treatment response of cancer [<xref ref-type="bibr" rid="CR88">88</xref>&#x02013;<xref ref-type="bibr" rid="CR90">90</xref>]. In CRC research, genomic data can provide key insights into the molecular characteristics of tumors, mutations, and drug sensitivity. (3) The study was single-center, and results from a single-center study may not be generalizable to other populations, healthcare settings, or geographic regions.</p><p id="Par41">Future research should incorporate genomic data to gain a more comprehensive understanding of the molecular characteristics of tumors, mutations, and drug sensitivity. Moreover, since this study was conducted at a single center, its findings may not be fully applicable to other populations, healthcare settings, or geographic regions. Therefore, multi-center studies involving diverse populations are essential to validate these results and improve the robustness and generalizability of the predictive model across various clinical environments.</p></sec><sec id="Sec26"><title>Conclusions</title><p id="Par42">In the study, WST, HT, CAE at last-FU, and Pre-AGR were identified as independent risk factors of extensive metastasis in OMCRC. The COX model can predict extensive metastasis with good discrimination and calibration. The model&#x02019;s nomogram enables dynamic and accurate prediction of the risk of extensive metastasis, assisting clinicians in providing optimal personalized treatment.</p></sec><sec id="Sec27" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="384_2025_4841_MOESM1_ESM.pdf"><label>ESM 1</label><caption><p>(PDF 1.49 MB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="384_2025_4841_MOESM2_ESM.pdf"><label>ESM 2</label><caption><p>(PDF 203 KB)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>All statistical analyses in this study were independently conducted by the authors using publicly available R packages. We gratefully acknowledge the developers of these R packages for their contributions to the scientific community.</p></ack><notes notes-type="author-contribution"><title>Author contribution</title><p>Conceptualization: FRC; Data curation, FRC, ZJQ, DM, ZR, WXR and DJX; Formal analysis: FRC, MCK, DM and DJX; Funding acquisition: LSC and ZZX; Investigation: MCK, ZJQ, ZR and WXR; Methodology: FRC; Project administration: MCK, DM, WXR, DJX, LSC and ZZX; Resources: ZJQ, LSC and ZZX; Software: FRC; Supervision: LSC and ZZX; Validation: MCK; Visualization: ZJQ and ZR; Writing &#x02013; original draft: FRC; Writing &#x02013; review &#x00026; editing: LSC and ZZX.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the Science and Technology Program of Suzhou (grant number SLT201933), the Gusu Health Talent Research Fund (grant number GSWS2023097), and the Pre-research Project for Doctoral and Returned Overseas Students at the Second Affiliated Hospital of Soochow University (grant number SDFEYBS2210).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval</title><p id="Par43">This study was approved by the local ethics committee under approval number (JD-HG-2024&#x02013;034). Informed consent was obtained from the patients upon admission, consenting to the use of their medical records for research purposes. According to national legislation and institutional requirements, patients or their legal guardians/next of kin were not required to provide a written informed consent form for participation in this study.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par44">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Sung H, Ferlay J, Siegel R L, et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin 71(3):209&#x02013;249</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name></person-group><article-title>Global colorectal cancer burden in 2020 and projections to 2040[J]</article-title><source>Transl Oncol</source><year>2021</year><volume>14</volume><issue>10</issue><fpage>101174</fpage><pub-id pub-id-type="doi">10.1016/j.tranon.2021.101174</pub-id><pub-id pub-id-type="pmid">34243011</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Xi Y, Xu P (2021) Global colorectal cancer burden in 2020 and projections to 2040[J]. Transl Oncol 14(10):101174<pub-id pub-id-type="pmid">34243011</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Ciardiello F, Ciardiello D, Martini G, et al (2022) Clinical management of metastatic colorectal cancer in the era of precision medicine[J]. CA Cancer J Clin 72(4):372&#x02013;401</mixed-citation></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Cervantes</surname><given-names>A</given-names></name><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Rosell&#x000f3;</surname><given-names>S</given-names></name><etal/></person-group><article-title>Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]</article-title><source>Ann Oncol</source><year>2023</year><volume>34</volume><issue>1</issue><fpage>10</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2022.10.003</pub-id><pub-id pub-id-type="pmid">36307056</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Cervantes A, Adam R, Rosell&#x000f3; S et al (2023) Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]. Ann Oncol 34(1):10&#x02013;32<pub-id pub-id-type="pmid">36307056</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>V&#x000e4;yrynen</surname><given-names>V</given-names></name><name><surname>Wirta</surname><given-names>E-V</given-names></name><name><surname>Sepp&#x000e4;l&#x000e4;</surname><given-names>T</given-names></name><etal/></person-group><article-title>Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases: a population-based study[J]</article-title><source>BJS Open</source><year>2020</year><volume>4</volume><issue>4</issue><fpage>685</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1002/bjs5.50299</pub-id><pub-id pub-id-type="pmid">32543788</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">V&#x000e4;yrynen V, Wirta E-V, Sepp&#x000e4;l&#x000e4; T et al (2020) Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases: a population-based study[J]. BJS Open 4(4):685&#x02013;692<pub-id pub-id-type="pmid">32543788</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Sorbye</surname><given-names>H</given-names></name><name><surname>K&#x000f6;hne</surname><given-names>C-H</given-names></name><name><surname>Sargent</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification[J]</article-title><source>Ann Oncol</source><year>2007</year><volume>18</volume><issue>10</issue><fpage>1666</fpage><lpage>1672</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdm267</pub-id><pub-id pub-id-type="pmid">17660495</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Sorbye H, K&#x000f6;hne C-H, Sargent DJ et al (2007) Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification[J]. Ann Oncol 18(10):1666&#x02013;1672<pub-id pub-id-type="pmid">17660495</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Osterlund</surname><given-names>P</given-names></name><name><surname>Salminen</surname><given-names>T</given-names></name><name><surname>Soveri</surname><given-names>L-M</given-names></name><etal/></person-group><article-title>Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): a nationwide prospective intervention study[J]</article-title><source>Lancet Reg Health Eur</source><year>2021</year><volume>3</volume><fpage>100049</fpage><pub-id pub-id-type="doi">10.1016/j.lanepe.2021.100049</pub-id><pub-id pub-id-type="pmid">34557799</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Osterlund P, Salminen T, Soveri L-M et al (2021) Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): a nationwide prospective intervention study[J]. Lancet Reg Health Eur 3:100049<pub-id pub-id-type="pmid">34557799</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Haggar</surname><given-names>FA</given-names></name><name><surname>Boushey</surname><given-names>RP</given-names></name></person-group><article-title>Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors[J]</article-title><source>Clin Colon Rectal Surg</source><year>2009</year><volume>22</volume><issue>4</issue><fpage>191</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1055/s-0029-1242458</pub-id><pub-id pub-id-type="pmid">21037809</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Haggar FA, Boushey RP (2009) Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors[J]. Clin Colon Rectal Surg 22(4):191&#x02013;197<pub-id pub-id-type="pmid">21037809</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>VK</given-names></name><name><surname>Kennedy</surname><given-names>EB</given-names></name><name><surname>Baxter</surname><given-names>NN</given-names></name><etal/></person-group><article-title>Treatment of metastatic colorectal cancer: ASCO guideline[J]</article-title><source>J Clin Oncol</source><year>2023</year><volume>41</volume><issue>3</issue><fpage>678</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1200/JCO.22.01690</pub-id><pub-id pub-id-type="pmid">36252154</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Morris VK, Kennedy EB, Baxter NN et al (2023) Treatment of metastatic colorectal cancer: ASCO guideline[J]. J Clin Oncol 41(3):678&#x02013;700<pub-id pub-id-type="pmid">36252154</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Stewart C L, Warner S, Ito K, et al (2018) Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?[J]. Curr Prob Surg 55(9):330&#x02013;379</mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Benson A B, Venook A P, Al-Hawary M M, et al (2020) NCCN guidelines insights: rectal cancer, Version 6.2020[J]. J Natl Compr Cancer Netw 18(7):806&#x02013;815</mixed-citation></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshino</surname><given-names>T</given-names></name><name><surname>Arnold</surname><given-names>D</given-names></name><name><surname>Taniguchi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS[J]</article-title><source>Ann Oncol</source><year>2018</year><volume>29</volume><issue>1</issue><fpage>44</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdx738</pub-id><pub-id pub-id-type="pmid">29155929</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Yoshino T, Arnold D, Taniguchi H et al (2018) Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS[J]. Ann Oncol 29(1):44&#x02013;70<pub-id pub-id-type="pmid">29155929</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Weiss J M, Gupta S, Burke C A, et al (2021) NCCN Guidelines&#x000ae; insights: genetic/familial high-risk assessment: colorectal, Version 1.2021[J]. J Natl Compr Cancer Netw 19(10):1122&#x02013;1132</mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Vigan&#x000f2;</surname><given-names>L</given-names></name><name><surname>Capussotti</surname><given-names>L</given-names></name><name><surname>Barroso</surname><given-names>E</given-names></name><etal/></person-group><article-title>Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases[J]</article-title><source>Ann Surg Oncol</source><year>2012</year><volume>19</volume><issue>9</issue><fpage>2786</fpage><lpage>2796</lpage><pub-id pub-id-type="doi">10.1245/s10434-012-2382-7</pub-id><pub-id pub-id-type="pmid">22622469</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Vigan&#x000f2; L, Capussotti L, Barroso E et al (2012) Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases[J]. Ann Surg Oncol 19(9):2786&#x02013;2796<pub-id pub-id-type="pmid">22622469</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Biller</surname><given-names>LH</given-names></name><name><surname>Schrag</surname><given-names>D</given-names></name></person-group><article-title>Diagnosis and treatment of metastatic colorectal cancer: a review[J]</article-title><source>JAMA</source><year>2021</year><volume>325</volume><issue>7</issue><fpage>669</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.0106</pub-id><pub-id pub-id-type="pmid">33591350</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Biller LH, Schrag D (2021) Diagnosis and treatment of metastatic colorectal cancer: a review[J]. JAMA 325(7):669&#x02013;685<pub-id pub-id-type="pmid">33591350</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>Y-J</given-names></name><name><surname>Bae</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Ki-67, 21-gene recurrence score, endocrine resistance, and survival in patients with breast cancer[J]</article-title><source>JAMA Netw Open</source><year>2023</year><volume>6</volume><issue>8</issue><fpage>e2330961</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.30961</pub-id><pub-id pub-id-type="pmid">37647069</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Lee J, Lee Y-J, Bae SJ et al (2023) Ki-67, 21-gene recurrence score, endocrine resistance, and survival in patients with breast cancer[J]. JAMA Netw Open 6(8):e2330961<pub-id pub-id-type="pmid">37647069</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Fong Y, Fortner J, Sun R L, et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases[J]. Ann Surg 230(3):309&#x02013;318; discussion 318&#x02013;321</mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Hasuike</surname><given-names>N</given-names></name><name><surname>Ono</surname><given-names>H</given-names></name><name><surname>Boku</surname><given-names>N</given-names></name><etal/></person-group><article-title>A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607)[J]</article-title><source>Gastric Cancer</source><year>2018</year><volume>21</volume><issue>1</issue><fpage>114</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1007/s10120-017-0704-y</pub-id><pub-id pub-id-type="pmid">28224238</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Hasuike N, Ono H, Boku N et al (2018) A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607)[J]. Gastric Cancer 21(1):114&#x02013;123<pub-id pub-id-type="pmid">28224238</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelfatah</surname><given-names>MM</given-names></name><name><surname>Barakat</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><etal/></person-group><article-title>The incidence of lymph node metastasis in early gastric cancer according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association: a systematic review of the literature and meta-analysis[J]</article-title><source>Gastrointest Endosc</source><year>2018</year><volume>87</volume><issue>2</issue><fpage>338</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2017.09.025</pub-id><pub-id pub-id-type="pmid">28966062</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Abdelfatah MM, Barakat M, Lee H et al (2018) The incidence of lymph node metastasis in early gastric cancer according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association: a systematic review of the literature and meta-analysis[J]. Gastrointest Endosc 87(2):338&#x02013;347<pub-id pub-id-type="pmid">28966062</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Hatta</surname><given-names>W</given-names></name><name><surname>Gotoda</surname><given-names>T</given-names></name><name><surname>Oyama</surname><given-names>T</given-names></name><etal/></person-group><article-title>A scoring system to stratify curability after endoscopic submucosal dissection for early gastric cancer:&#x0300a;eCura system&#x0300b;[J]</article-title><source>Am J Gastroenterol</source><year>2017</year><volume>112</volume><issue>6</issue><fpage>874</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1038/ajg.2017.95</pub-id><pub-id pub-id-type="pmid">28397873</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Hatta W, Gotoda T, Oyama T et al (2017) A scoring system to stratify curability after endoscopic submucosal dissection for early gastric cancer:&#x0300a;eCura system&#x0300b;[J]. Am J Gastroenterol 112(6):874&#x02013;881<pub-id pub-id-type="pmid">28397873</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>IDO1/COX2 expression is associated with poor prognosis in colorectal cancer liver oligometastases[J]</article-title><source>J Personalized Med</source><year>2023</year><volume>13</volume><issue>3</issue><fpage>496</fpage><pub-id pub-id-type="doi">10.3390/jpm13030496</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Wu M, Wu X, Wang X et al (2023) IDO1/COX2 expression is associated with poor prognosis in colorectal cancer liver oligometastases[J]. J Personalized Med 13(3):496</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Outcomes of stereotactic body radiotherapy for metastatic colorectal cancer with oligometastases, oligoprogression, or local control of dominant tumors[J]</article-title><source>Front Oncol</source><year>2020</year><volume>10</volume><fpage>595781</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.595781</pub-id><pub-id pub-id-type="pmid">33585211</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Ji X, Zhao Y, Zhu X et al (2020) Outcomes of stereotactic body radiotherapy for metastatic colorectal cancer with oligometastases, oligoprogression, or local control of dominant tumors[J]. Front Oncol 10:595781<pub-id pub-id-type="pmid">33585211</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Ou</surname><given-names>Q</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>TROP2 overexpression in colorectal liver oligometastases is associated with poor prognosis after liver resection[J]</article-title><source>Ther Adv Med Oncol</source><year>2019</year><volume>11</volume><fpage>1758835919897543</fpage><pub-id pub-id-type="doi">10.1177/1758835919897543</pub-id><pub-id pub-id-type="pmid">35173815</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Peng J, Ou Q, Deng Y et al (2019) TROP2 overexpression in colorectal liver oligometastases is associated with poor prognosis after liver resection[J]. Ther Adv Med Oncol 11:1758835919897543<pub-id pub-id-type="pmid">35173815</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>J-H</given-names></name><name><surname>Tai</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Y-X</given-names></name><etal/></person-group><article-title>Programmed death-ligand 1 expression in the tumour stroma of colorectal liver oligometastases and its association with prognosis after liver resection[J]</article-title><source>Gastroenterol Rep</source><year>2021</year><volume>9</volume><issue>5</issue><fpage>443</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1093/gastro/goaa077</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Peng J-H, Tai Y, Zhao Y-X et al (2021) Programmed death-ligand 1 expression in the tumour stroma of colorectal liver oligometastases and its association with prognosis after liver resection[J]. Gastroenterol Rep 9(5):443&#x02013;450</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Z</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><etal/></person-group><article-title>Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?[J]</article-title><source>Cancer Commun (Lond)</source><year>2018</year><volume>38</volume><issue>1</issue><fpage>29</fpage><pub-id pub-id-type="pmid">29843800</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Pan Z, Peng J, Lin J et al (2018) Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?[J]. Cancer Commun (Lond) 38(1):29<pub-id pub-id-type="pmid">29843800</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Londero</surname><given-names>F</given-names></name><name><surname>Parise</surname><given-names>O</given-names></name><name><surname>Grossi</surname><given-names>W</given-names></name><etal/></person-group><article-title>The role of obesity in early and long-term outcomes after surgical excision of lung oligometastases from colorectal cancer[J]</article-title><source>J Clin Med</source><year>2020</year><volume>9</volume><issue>11</issue><fpage>3566</fpage><pub-id pub-id-type="doi">10.3390/jcm9113566</pub-id><pub-id pub-id-type="pmid">33167545</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Londero F, Parise O, Grossi W et al (2020) The role of obesity in early and long-term outcomes after surgical excision of lung oligometastases from colorectal cancer[J]. J Clin Med 9(11):3566<pub-id pub-id-type="pmid">33167545</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Filippini Vel&#x000e1;zquez</surname><given-names>G</given-names></name><name><surname>Schiele</surname><given-names>S</given-names></name><name><surname>Gerken</surname><given-names>M</given-names></name><etal/></person-group><article-title>Predictive preoperative clinical score for patients with liver-only oligometastatic colorectal cancer[J]</article-title><source>ESMO Open</source><year>2022</year><volume>7</volume><issue>3</issue><fpage>100470</fpage><pub-id pub-id-type="doi">10.1016/j.esmoop.2022.100470</pub-id><pub-id pub-id-type="pmid">35461024</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Filippini Vel&#x000e1;zquez G, Schiele S, Gerken M et al (2022) Predictive preoperative clinical score for patients with liver-only oligometastatic colorectal cancer[J]. ESMO Open 7(3):100470<pub-id pub-id-type="pmid">35461024</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DK</given-names></name></person-group><article-title>Data transformation: a focus on the interpretation[J]</article-title><source>Korean J Anesthesiol</source><year>2020</year><volume>73</volume><issue>6</issue><fpage>503</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.4097/kja.20137</pub-id><pub-id pub-id-type="pmid">33271009</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Lee DK (2020) Data transformation: a focus on the interpretation[J]. Korean J Anesthesiol 73(6):503&#x02013;508<pub-id pub-id-type="pmid">33271009</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Olivier</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>WD</given-names></name><name><surname>Marshall</surname><given-names>GD</given-names></name></person-group><article-title>The logarithmic transformation and the geometric mean in reporting experimental IgE results: what are they and when and why to use them?[J]</article-title><source>Ann Allergy Asthma Immunol</source><year>2008</year><volume>100</volume><issue>4</issue><fpage>333</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/S1081-1206(10)60595-9</pub-id><pub-id pub-id-type="pmid">18450118</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Olivier J, Johnson WD, Marshall GD (2008) The logarithmic transformation and the geometric mean in reporting experimental IgE results: what are they and when and why to use them?[J]. Ann Allergy Asthma Immunol 100(4):333&#x02013;337<pub-id pub-id-type="pmid">18450118</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Sterne</surname><given-names>JAC</given-names></name><name><surname>White</surname><given-names>IR</given-names></name><name><surname>Carlin</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls[J]</article-title><source>BMJ (Clin Res Ed)</source><year>2009</year><volume>338</volume><fpage>b2393</fpage><pub-id pub-id-type="doi">10.1136/bmj.b2393</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Sterne JAC, White IR, Carlin JB et al (2009) Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls[J]. BMJ (Clin Res Ed) 338:b2393</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Madley-Dowd</surname><given-names>P</given-names></name><name><surname>Hughes</surname><given-names>R</given-names></name><name><surname>Tilling</surname><given-names>K</given-names></name><etal/></person-group><article-title>The proportion of missing data should not be used to guide decisions on multiple imputation[J]</article-title><source>J Clin Epidemiol</source><year>2019</year><volume>110</volume><fpage>63</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2019.02.016</pub-id><pub-id pub-id-type="pmid">30878639</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Madley-Dowd P, Hughes R, Tilling K et al (2019) The proportion of missing data should not be used to guide decisions on multiple imputation[J]. J Clin Epidemiol 110:63&#x02013;73<pub-id pub-id-type="pmid">30878639</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Blazek</surname><given-names>K</given-names></name><name><surname>van Zwieten</surname><given-names>A</given-names></name><name><surname>Saglimbene</surname><given-names>V</given-names></name><etal/></person-group><article-title>A practical guide to multiple imputation of missing data in nephrology[J]</article-title><source>Kidney Int</source><year>2021</year><volume>99</volume><issue>1</issue><fpage>68</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2020.07.035</pub-id><pub-id pub-id-type="pmid">32822702</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Blazek K, van Zwieten A, Saglimbene V et al (2021) A practical guide to multiple imputation of missing data in nephrology[J]. Kidney Int 99(1):68&#x02013;74<pub-id pub-id-type="pmid">32822702</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>G</given-names></name><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Evaluation and analysis of incidence and risk factors of lower extremity venous thrombosis after urologic surgeries: a prospective two-center cohort study using LASSO-logistic regression[J]</article-title><source>Int J Surg (Lond)</source><year>2021</year><volume>89</volume><fpage>105948</fpage><pub-id pub-id-type="doi">10.1016/j.ijsu.2021.105948</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Tang G, Qi L, Sun Z et al (2021) Evaluation and analysis of incidence and risk factors of lower extremity venous thrombosis after urologic surgeries: a prospective two-center cohort study using LASSO-logistic regression[J]. Int J Surg (Lond) 89:105948</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Tibshirani</surname><given-names>R</given-names></name></person-group><article-title>Regression shrinkage and selection via the Lasso[J]</article-title><source>J Roy Stat Soc: Ser B (Methodol)</source><year>1996</year><volume>58</volume><issue>1</issue><fpage>267</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1111/j.2517-6161.1996.tb02080.x</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Tibshirani R (1996) Regression shrinkage and selection via the Lasso[J]. J Roy Stat Soc: Ser B (Methodol) 58(1):267&#x02013;288</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Ranstam</surname><given-names>J</given-names></name><name><surname>Cook</surname><given-names>JA</given-names></name></person-group><article-title>Kaplan-Meier curve[J]</article-title><source>Br J Surg</source><year>2017</year><volume>104</volume><issue>4</issue><fpage>442</fpage><pub-id pub-id-type="doi">10.1002/bjs.10238</pub-id><pub-id pub-id-type="pmid">28199017</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Ranstam J, Cook JA (2017) Kaplan-Meier curve[J]. Br J Surg 104(4):442<pub-id pub-id-type="pmid">28199017</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Schober</surname><given-names>P</given-names></name><name><surname>Vetter</surname><given-names>TR</given-names></name></person-group><article-title>Kaplan-Meier curves, log-rank tests, and cox regression for time-to-event data[J]</article-title><source>Anesth Analg</source><year>2021</year><volume>132</volume><issue>4</issue><fpage>969</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1213/ANE.0000000000005358</pub-id><pub-id pub-id-type="pmid">33723194</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Schober P, Vetter TR (2021) Kaplan-Meier curves, log-rank tests, and cox regression for time-to-event data[J]. Anesth Analg 132(4):969&#x02013;970<pub-id pub-id-type="pmid">33723194</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Timsit</surname><given-names>JF</given-names></name><name><surname>Alberti</surname><given-names>C</given-names></name><name><surname>Chevret</surname><given-names>S</given-names></name></person-group><article-title>Cox proportional hazards regression analysis[J]</article-title><source>Rev Mal Respir</source><year>2005</year><volume>22</volume><issue>6 Pt 1</issue><fpage>1058</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1016/S0761-8425(05)85739-0</pub-id><pub-id pub-id-type="pmid">16227945</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Timsit JF, Alberti C, Chevret S (2005) Cox proportional hazards regression analysis[J]. Rev Mal Respir 22(6 Pt 1):1058&#x02013;1064<pub-id pub-id-type="pmid">16227945</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Chen T, Guestrin C (2016) XGBoost: a scalable tree boosting system[A]. Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining[C]. Association for Computing Machinery, New York, pp 785&#x02013;794</mixed-citation></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Noble</surname><given-names>WS</given-names></name></person-group><article-title>What is a support vector machine?[J]</article-title><source>Nat Biotechnol</source><year>2006</year><volume>24</volume><issue>12</issue><fpage>1565</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1038/nbt1206-1565</pub-id><pub-id pub-id-type="pmid">17160063</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Noble WS (2006) What is a support vector machine?[J]. Nat Biotechnol 24(12):1565&#x02013;1567<pub-id pub-id-type="pmid">17160063</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Novel models by machine learning to predict prognosis of breast cancer brain metastases[J]</article-title><source>J Transl Med</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>404</fpage><pub-id pub-id-type="doi">10.1186/s12967-023-04277-2</pub-id><pub-id pub-id-type="pmid">37344847</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Li C, Liu M, Zhang Y et al (2023) Novel models by machine learning to predict prognosis of breast cancer brain metastases[J]. J Transl Med 21(1):404<pub-id pub-id-type="pmid">37344847</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Van Belle</surname><given-names>V</given-names></name><name><surname>Pelckmans</surname><given-names>K</given-names></name><name><surname>Van Huffel</surname><given-names>S</given-names></name><etal/></person-group><article-title>Support vector methods for survival analysis: a comparison between ranking and regression approaches[J]</article-title><source>Artif Intell Med</source><year>2011</year><volume>53</volume><issue>2</issue><fpage>107</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.artmed.2011.06.006</pub-id><pub-id pub-id-type="pmid">21821401</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Van Belle V, Pelckmans K, Van Huffel S et al (2011) Support vector methods for survival analysis: a comparison between ranking and regression approaches[J]. Artif Intell Med 53(2):107&#x02013;118<pub-id pub-id-type="pmid">21821401</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Van Belle</surname><given-names>V</given-names></name><name><surname>Pelckmans</surname><given-names>K</given-names></name><name><surname>Van Huffel</surname><given-names>S</given-names></name><etal/></person-group><article-title>Improved performance on high-dimensional survival data by application of Survival-SVM[J]</article-title><source>Bioinformatics (Oxf)</source><year>2011</year><volume>27</volume><issue>1</issue><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq617</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Van Belle V, Pelckmans K, Van Huffel S et al (2011) Improved performance on high-dimensional survival data by application of Survival-SVM[J]. Bioinformatics (Oxf) 27(1):87&#x02013;94</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Alba</surname><given-names>AC</given-names></name><name><surname>Agoritsas</surname><given-names>T</given-names></name><name><surname>Walsh</surname><given-names>M</given-names></name><etal/></person-group><article-title>Discrimination and calibration of clinical prediction models: users&#x02019; guides to the medical literature[J]</article-title><source>JAMA</source><year>2017</year><volume>318</volume><issue>14</issue><fpage>1377</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.1001/jama.2017.12126</pub-id><pub-id pub-id-type="pmid">29049590</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Alba AC, Agoritsas T, Walsh M et al (2017) Discrimination and calibration of clinical prediction models: users&#x02019; guides to the medical literature[J]. JAMA 318(14):1377&#x02013;1384<pub-id pub-id-type="pmid">29049590</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Van Calster</surname><given-names>B</given-names></name><name><surname>Wynants</surname><given-names>L</given-names></name><name><surname>Verbeek</surname><given-names>JFM</given-names></name><etal/></person-group><article-title>Reporting and interpreting decision curve analysis: a guide for investigators[J]</article-title><source>Eur Urol</source><year>2018</year><volume>74</volume><issue>6</issue><fpage>796</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2018.08.038</pub-id><pub-id pub-id-type="pmid">30241973</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Van Calster B, Wynants L, Verbeek JFM et al (2018) Reporting and interpreting decision curve analysis: a guide for investigators[J]. Eur Urol 74(6):796&#x02013;804<pub-id pub-id-type="pmid">30241973</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Harrell</surname><given-names>FE</given-names></name><name><surname>Califf</surname><given-names>RM</given-names></name><name><surname>Pryor</surname><given-names>DB</given-names></name><etal/></person-group><article-title>Evaluating the yield of medical tests[J]</article-title><source>JAMA</source><year>1982</year><volume>247</volume><issue>18</issue><fpage>2543</fpage><lpage>2546</lpage><pub-id pub-id-type="doi">10.1001/jama.1982.03320430047030</pub-id><pub-id pub-id-type="pmid">7069920</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Harrell FE, Califf RM, Pryor DB et al (1982) Evaluating the yield of medical tests[J]. JAMA 247(18):2543&#x02013;2546<pub-id pub-id-type="pmid">7069920</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Balachandran</surname><given-names>VP</given-names></name><name><surname>Gonen</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Nomograms in oncology: more than meets the eye[J]</article-title><source>Lancet Oncol</source><year>2015</year><volume>16</volume><issue>4</issue><fpage>e173</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)71116-7</pub-id><pub-id pub-id-type="pmid">25846097</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Balachandran VP, Gonen M, Smith JJ et al (2015) Nomograms in oncology: more than meets the eye[J]. Lancet Oncol 16(4):e173-180<pub-id pub-id-type="pmid">25846097</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>J</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name></person-group><article-title>Regularization paths for generalized linear models via coordinate descent[J]</article-title><source>J Stat Softw</source><year>2010</year><volume>33</volume><issue>1</issue><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.18637/jss.v033.i01</pub-id><pub-id pub-id-type="pmid">20808728</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Friedman J, Hastie T, Tibshirani R (2010) Regularization paths for generalized linear models via coordinate descent[J]. J Stat Softw 33(1):1&#x02013;22<pub-id pub-id-type="pmid">20808728</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Tay</surname><given-names>JK</given-names></name><name><surname>Narasimhan</surname><given-names>B</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name></person-group><article-title>Elastic net regularization paths for all generalized linear models[J]</article-title><source>J Stat Softw</source><year>2023</year><volume>106</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.18637/jss.v106.i01</pub-id><pub-id pub-id-type="pmid">37138589</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Tay JK, Narasimhan B, Hastie T (2023) Elastic net regularization paths for all generalized linear models[J]. J Stat Softw 106:1<pub-id pub-id-type="pmid">37138589</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Therneau TM, Grambsch PM (2000) Modeling survival data: extending the Cox model. Springer, New York (ISBN 0-387-98784-3)</mixed-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="other">Therneau T (2024) A package for survival analysis in R. R package version 3.5&#x02013;8. <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=survival">https://CRAN.R-project.org/package=survival</ext-link>. Accessed 18 Mar 2024</mixed-citation></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="other">Chen T, He T, Benesty M, et al (2024) xgboost: extreme gradient boosting. R package version 1.7.7.1. <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=xgboost">https://CRAN.R-project.org/package=xgboost</ext-link>. Accessed 18 Mar 2024</mixed-citation></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Fouodo C J K (2018) Survivalsvm: survival support vector analysis. R package version 0.0.5. <ext-link ext-link-type="uri" xlink:href="https://github.com/imbs-hl/survivalsvm">https://github.com/imbs-hl/survivalsvm</ext-link>. Accessed 18 Mar 2024</mixed-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">Harrell Jr FE (2024) rms: Regression modeling strategies. R package version 6.8&#x02013;0. <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=rms">https://CRAN.R-project.org/package=rms</ext-link>. Accessed 18 Mar 2024</mixed-citation></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Fidler</surname><given-names>MM</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><article-title>A global view on cancer incidence and national levels of the human development index[J]</article-title><source>Int J Cancer</source><year>2016</year><volume>139</volume><issue>11</issue><fpage>2436</fpage><lpage>2446</lpage><pub-id pub-id-type="doi">10.1002/ijc.30382</pub-id><pub-id pub-id-type="pmid">27522007</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Fidler MM, Soerjomataram I, Bray F (2016) A global view on cancer incidence and national levels of the human development index[J]. Int J Cancer 139(11):2436&#x02013;2446<pub-id pub-id-type="pmid">27522007</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Atkin</surname><given-names>W</given-names></name><name><surname>Lenz</surname><given-names>H-J</given-names></name><etal/></person-group><article-title>Colorectal cancer[J]</article-title><source>Lancet (Lond)</source><year>2010</year><volume>375</volume><issue>9719</issue><fpage>1030</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60353-4</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Cunningham D, Atkin W, Lenz H-J et al (2010) Colorectal cancer[J]. Lancet (Lond) 375(9719):1030&#x02013;1047</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="other">Wang X, Chi P, Lin H, et al (2017) Establishment of nomogram model to predict peritoneal metastasis in colon cancer patients without distant metastasis by preoperative imaging examination[J]. Zhonghua Wei Chang Wai Ke Za Zhi = Chin J Gastrointest Surg 20(12):1387&#x02013;1392</mixed-citation></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Goossens-Beumer</surname><given-names>IJ</given-names></name><name><surname>Derr</surname><given-names>RS</given-names></name><name><surname>Buermans</surname><given-names>HPJ</given-names></name><etal/></person-group><article-title>MicroRNA classifier and nomogram for metastasis prediction in colon cancer[J]</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2015</year><volume>24</volume><issue>1</issue><fpage>187</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-14-0544-T</pub-id><pub-id pub-id-type="pmid">25315964</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Goossens-Beumer IJ, Derr RS, Buermans HPJ et al (2015) MicroRNA classifier and nomogram for metastasis prediction in colon cancer[J]. Cancer Epidemiol Biomarkers Prev 24(1):187&#x02013;197<pub-id pub-id-type="pmid">25315964</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Macias-Garcia</surname><given-names>F</given-names></name><name><surname>Celeiro-Mu&#x000f1;oz</surname><given-names>C</given-names></name><name><surname>Lesquereux-Martinez</surname><given-names>L</given-names></name><etal/></person-group><article-title>A clinical model for predicting lymph node metastasis in submucosal invasive (T1) colorectal cancer[J]</article-title><source>Int J Colorectal Dis</source><year>2015</year><volume>30</volume><issue>6</issue><fpage>761</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1007/s00384-015-2164-3</pub-id><pub-id pub-id-type="pmid">25700808</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Macias-Garcia F, Celeiro-Mu&#x000f1;oz C, Lesquereux-Martinez L et al (2015) A clinical model for predicting lymph node metastasis in submucosal invasive (T1) colorectal cancer[J]. Int J Colorectal Dis 30(6):761&#x02013;768<pub-id pub-id-type="pmid">25700808</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Segelman</surname><given-names>J</given-names></name><name><surname>Akre</surname><given-names>O</given-names></name><name><surname>Gustafsson</surname><given-names>UO</given-names></name><etal/></person-group><article-title>Individualized prediction of risk ofmetachronous peritoneal carcinomatosis from colorectal cancer[J]</article-title><source>Colorectal Dis</source><year>2014</year><volume>16</volume><issue>5</issue><fpage>359</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1111/codi.12552</pub-id><pub-id pub-id-type="pmid">24410859</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Segelman J, Akre O, Gustafsson UO et al (2014) Individualized prediction of risk ofmetachronous peritoneal carcinomatosis from colorectal cancer[J]. Colorectal Dis 16(5):359&#x02013;367<pub-id pub-id-type="pmid">24410859</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>C-X</given-names></name><name><surname>Quan</surname><given-names>J-C</given-names></name><etal/></person-group><article-title>A clinical model to predict the risk of synchronous bone metastasis in newly diagnosed colorectal cancer: a population-based study[J]</article-title><source>BMC Cancer</source><year>2019</year><volume>19</volume><issue>1</issue><fpage>704</fpage><pub-id pub-id-type="doi">10.1186/s12885-019-5912-x</pub-id><pub-id pub-id-type="pmid">31315606</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Guan X, Ma C-X, Quan J-C et al (2019) A clinical model to predict the risk of synchronous bone metastasis in newly diagnosed colorectal cancer: a population-based study[J]. BMC Cancer 19(1):704<pub-id pub-id-type="pmid">31315606</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>van Gijn</surname><given-names>W</given-names></name><name><surname>van Stiphout</surname><given-names>RGPM</given-names></name><name><surname>van de Velde</surname><given-names>CJH</given-names></name><etal/></person-group><article-title>Nomograms to predict survival and the risk for developing local or distant recurrence in patients with rectal cancer treated with optional short-term radiotherapy[J]</article-title><source>Ann Oncol</source><year>2015</year><volume>26</volume><issue>5</issue><fpage>928</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdv023</pub-id><pub-id pub-id-type="pmid">25609247</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">van Gijn W, van Stiphout RGPM, van de Velde CJH et al (2015) Nomograms to predict survival and the risk for developing local or distant recurrence in patients with rectal cancer treated with optional short-term radiotherapy[J]. Ann Oncol 26(5):928&#x02013;935<pub-id pub-id-type="pmid">25609247</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Valentini</surname><given-names>V</given-names></name><name><surname>van Stiphout</surname><given-names>RGPM</given-names></name><name><surname>Lammering</surname><given-names>G</given-names></name><etal/></person-group><article-title>Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials[J]</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><issue>23</issue><fpage>3163</fpage><lpage>3172</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.33.1595</pub-id><pub-id pub-id-type="pmid">21747092</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Valentini V, van Stiphout RGPM, Lammering G et al (2011) Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials[J]. J Clin Oncol 29(23):3163&#x02013;3172<pub-id pub-id-type="pmid">21747092</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Miyoshi</surname><given-names>N</given-names></name><name><surname>Ohue</surname><given-names>M</given-names></name><name><surname>Yasui</surname><given-names>M</given-names></name><etal/></person-group><article-title>Novel prognostic prediction models for patients with stage IV colorectal cancer after concurrent curative resection[J]</article-title><source>ESMO Open</source><year>2016</year><volume>1</volume><issue>3</issue><fpage>e000052</fpage><pub-id pub-id-type="doi">10.1136/esmoopen-2016-000052</pub-id><pub-id pub-id-type="pmid">27843609</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Miyoshi N, Ohue M, Yasui M et al (2016) Novel prognostic prediction models for patients with stage IV colorectal cancer after concurrent curative resection[J]. ESMO Open 1(3):e000052<pub-id pub-id-type="pmid">27843609</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Hida</surname><given-names>K</given-names></name><name><surname>Okamura</surname><given-names>R</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><etal/></person-group><article-title>A new prediction model for local recurrence after curative rectal cancer surgery: development and validation as an asian collaborative study[J]</article-title><source>Dis Colon Rectum</source><year>2017</year><volume>60</volume><issue>11</issue><fpage>1168</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1097/DCR.0000000000000896</pub-id><pub-id pub-id-type="pmid">28991081</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Hida K, Okamura R, Park SY et al (2017) A new prediction model for local recurrence after curative rectal cancer surgery: development and validation as an asian collaborative study[J]. Dis Colon Rectum 60(11):1168&#x02013;1174<pub-id pub-id-type="pmid">28991081</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Hong</surname><given-names>SP</given-names></name><name><surname>Jeon</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Should a colonoscopy be recommended for healthy individuals with increased carcinoembryonic antigen levels? A case-control study[J]</article-title><source>Dig Dis Sci</source><year>2011</year><volume>56</volume><issue>8</issue><fpage>2396</fpage><lpage>2403</lpage><pub-id pub-id-type="doi">10.1007/s10620-011-1606-1</pub-id><pub-id pub-id-type="pmid">21327920</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Lee JH, Hong SP, Jeon TJ et al (2011) Should a colonoscopy be recommended for healthy individuals with increased carcinoembryonic antigen levels? A case-control study[J]. Dig Dis Sci 56(8):2396&#x02013;2403<pub-id pub-id-type="pmid">21327920</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><mixed-citation publication-type="other">Michl M, Stintzing S, Fischer von Weikersthal L, et al (2016) CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)[J]. Ann Oncol 27(8):1565&#x02013;1572</mixed-citation></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Pakdel</surname><given-names>A</given-names></name><name><surname>Malekzadeh</surname><given-names>M</given-names></name><name><surname>Naghibalhossaini</surname><given-names>F</given-names></name></person-group><article-title>The association between preoperative serum CEA concentrations and synchronous liver metastasis in colorectal cancer patients[J]</article-title><source>Cancer Biomark</source><year>2016</year><volume>16</volume><issue>2</issue><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.3233/CBM-150561</pub-id><pub-id pub-id-type="pmid">26756614</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Pakdel A, Malekzadeh M, Naghibalhossaini F (2016) The association between preoperative serum CEA concentrations and synchronous liver metastasis in colorectal cancer patients[J]. Cancer Biomark 16(2):245&#x02013;252<pub-id pub-id-type="pmid">26756614</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Stiksma</surname><given-names>J</given-names></name><name><surname>Grootendorst</surname><given-names>DC</given-names></name><name><surname>van der Linden</surname><given-names>PWG</given-names></name></person-group><article-title>CA 19&#x02013;9 as a marker in addition to CEA to monitor colorectal cancer[J]</article-title><source>Clin Colorectal Cancer</source><year>2014</year><volume>13</volume><issue>4</issue><fpage>239</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.clcc.2014.09.004</pub-id><pub-id pub-id-type="pmid">25442815</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Stiksma J, Grootendorst DC, van der Linden PWG (2014) CA 19&#x02013;9 as a marker in addition to CEA to monitor colorectal cancer[J]. Clin Colorectal Cancer 13(4):239&#x02013;244<pub-id pub-id-type="pmid">25442815</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>PC</given-names></name><name><surname>Rajab</surname><given-names>IM</given-names></name><name><surname>Alebraheem</surname><given-names>M</given-names></name><etal/></person-group><article-title>C-reactive protein and cancer-diagnostic and therapeutic insights[J]</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>595835</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.595835</pub-id><pub-id pub-id-type="pmid">33324413</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Hart PC, Rajab IM, Alebraheem M et al (2020) C-reactive protein and cancer-diagnostic and therapeutic insights[J]. Front Immunol 11:595835<pub-id pub-id-type="pmid">33324413</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Shibutani</surname><given-names>M</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Nagahara</surname><given-names>H</given-names></name><etal/></person-group><article-title>The prognostic significance of the postoperative prognostic nutritional index in patients with colorectal cancer[J]</article-title><source>BMC Cancer</source><year>2015</year><volume>15</volume><fpage>521</fpage><pub-id pub-id-type="doi">10.1186/s12885-015-1537-x</pub-id><pub-id pub-id-type="pmid">26177820</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Shibutani M, Maeda K, Nagahara H et al (2015) The prognostic significance of the postoperative prognostic nutritional index in patients with colorectal cancer[J]. BMC Cancer 15:521<pub-id pub-id-type="pmid">26177820</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Stotz</surname><given-names>M</given-names></name><name><surname>Pichler</surname><given-names>M</given-names></name><name><surname>Absenger</surname><given-names>G</given-names></name><etal/></person-group><article-title>The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer[J]</article-title><source>Br J Cancer</source><year>2014</year><volume>110</volume><issue>2</issue><fpage>435</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1038/bjc.2013.785</pub-id><pub-id pub-id-type="pmid">24357796</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Stotz M, Pichler M, Absenger G et al (2014) The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer[J]. Br J Cancer 110(2):435&#x02013;440<pub-id pub-id-type="pmid">24357796</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Emir</surname><given-names>S</given-names></name><name><surname>Aydin</surname><given-names>M</given-names></name><name><surname>Can</surname><given-names>G</given-names></name><etal/></person-group><article-title>Comparison of colorectal neoplastic polyps and adenocarcinoma with regard to NLR and PLR[J]</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2015</year><volume>19</volume><issue>19</issue><fpage>3613</fpage><lpage>3618</lpage><pub-id pub-id-type="pmid">26502851</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Emir S, Aydin M, Can G et al (2015) Comparison of colorectal neoplastic polyps and adenocarcinoma with regard to NLR and PLR[J]. Eur Rev Med Pharmacol Sci 19(19):3613&#x02013;3618<pub-id pub-id-type="pmid">26502851</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Kiriu</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Nagano</surname><given-names>T</given-names></name><etal/></person-group><article-title>The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer[J]</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><issue>2</issue><fpage>e0193018</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0193018</pub-id><pub-id pub-id-type="pmid">29447258</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Kiriu T, Yamamoto M, Nagano T et al (2018) The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer[J]. PLoS ONE 13(2):e0193018<pub-id pub-id-type="pmid">29447258</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Prediction models of colorectal cancer prognosis incorporating perioperative longitudinal serum tumor markers: a retrospective longitudinal cohort study[J]</article-title><source>BMC Med</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>63</fpage><pub-id pub-id-type="doi">10.1186/s12916-023-02773-2</pub-id><pub-id pub-id-type="pmid">36803500</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Li C, Zhao K, Zhang D et al (2023) Prediction models of colorectal cancer prognosis incorporating perioperative longitudinal serum tumor markers: a retrospective longitudinal cohort study[J]. BMC Med 21(1):63<pub-id pub-id-type="pmid">36803500</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Sushentsev</surname><given-names>N</given-names></name><name><surname>Rundo</surname><given-names>L</given-names></name><name><surname>Abrego</surname><given-names>L</given-names></name><etal/></person-group><article-title>Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance[J]</article-title><source>Eur Radiol</source><year>2023</year><volume>33</volume><issue>6</issue><fpage>3792</fpage><lpage>3800</lpage><pub-id pub-id-type="doi">10.1007/s00330-023-09438-x</pub-id><pub-id pub-id-type="pmid">36749370</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Sushentsev N, Rundo L, Abrego L et al (2023) Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance[J]. Eur Radiol 33(6):3792&#x02013;3800<pub-id pub-id-type="pmid">36749370</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H-Y</given-names></name><name><surname>Shi</surname><given-names>P</given-names></name><etal/></person-group><article-title>Long short-term memory model - a deep learning approach for medical data with irregularity in cancer predication with tumor markers[J]</article-title><source>Comput Biol Med</source><year>2022</year><volume>144</volume><fpage>105362</fpage><pub-id pub-id-type="doi">10.1016/j.compbiomed.2022.105362</pub-id><pub-id pub-id-type="pmid">35299045</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Wu X, Wang H-Y, Shi P et al (2022) Long short-term memory model - a deep learning approach for medical data with irregularity in cancer predication with tumor markers[J]. Comput Biol Med 144:105362<pub-id pub-id-type="pmid">35299045</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Osterman</surname><given-names>E</given-names></name><name><surname>Ekstr&#x000f6;m</surname><given-names>J</given-names></name><name><surname>Sj&#x000f6;blom</surname><given-names>T</given-names></name><etal/></person-group><article-title>Accurate population-based model for individual prediction of colon cancer recurrence[J]</article-title><source>Acta Oncol (Stockholm)</source><year>2021</year><volume>60</volume><issue>10</issue><fpage>1241</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1080/0284186X.2021.1953138</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Osterman E, Ekstr&#x000f6;m J, Sj&#x000f6;blom T et al (2021) Accurate population-based model for individual prediction of colon cancer recurrence[J]. Acta Oncol (Stockholm) 60(10):1241&#x02013;1249</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Clift</surname><given-names>AK</given-names></name><name><surname>Dodwell</surname><given-names>D</given-names></name><name><surname>Lord</surname><given-names>S</given-names></name><etal/></person-group><article-title>Development and internal-external validation of statistical and machine learning models for breast cancer prognostication: cohort study[J]</article-title><source>BMJ (Clin Res Ed)</source><year>2023</year><volume>381</volume><fpage>e073800</fpage></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Clift AK, Dodwell D, Lord S et al (2023) Development and internal-external validation of statistical and machine learning models for breast cancer prognostication: cohort study[J]. BMJ (Clin Res Ed) 381:e073800</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Shinji</surname><given-names>S</given-names></name><name><surname>Naito</surname><given-names>Z</given-names></name><name><surname>Ishiwata</surname><given-names>T</given-names></name><etal/></person-group><article-title>Neuroendocrine cell differentiation of poorly differentiated colorectal adenocarcinoma correlates with liver metastasis[J]</article-title><source>Int J Oncol</source><year>2006</year><volume>29</volume><issue>2</issue><fpage>357</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">16820877</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Shinji S, Naito Z, Ishiwata T et al (2006) Neuroendocrine cell differentiation of poorly differentiated colorectal adenocarcinoma correlates with liver metastasis[J]. Int J Oncol 29(2):357&#x02013;364<pub-id pub-id-type="pmid">16820877</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Yoon</surname><given-names>YS</given-names></name><name><surname>Hong</surname><given-names>S-M</given-names></name><etal/></person-group><article-title>Poorly differentiated colorectal cancers: correlation of microsatellite instability with clinicopathologic features and survival[J]</article-title><source>Am J Clin Pathol</source><year>2013</year><volume>140</volume><issue>3</issue><fpage>341</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1309/AJCP8P2DYNKGRBVI</pub-id><pub-id pub-id-type="pmid">23955452</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Xiao H, Yoon YS, Hong S-M et al (2013) Poorly differentiated colorectal cancers: correlation of microsatellite instability with clinicopathologic features and survival[J]. Am J Clin Pathol 140(3):341&#x02013;347<pub-id pub-id-type="pmid">23955452</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Ayez</surname><given-names>N</given-names></name><name><surname>van der Stok</surname><given-names>EP</given-names></name><name><surname>Gr&#x000fc;nhagen</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: clinical risk score as possible discriminator[J]</article-title><source>Eur J Surg Oncol</source><year>2015</year><volume>41</volume><issue>7</issue><fpage>859</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1016/j.ejso.2015.04.012</pub-id><pub-id pub-id-type="pmid">25979624</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Ayez N, van der Stok EP, Gr&#x000fc;nhagen DJ et al (2015) The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: clinical risk score as possible discriminator[J]. Eur J Surg Oncol 41(7):859&#x02013;867<pub-id pub-id-type="pmid">25979624</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Xuan</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><etal/></person-group><article-title>Combination of the preoperative albumin to globulin ratio and neutrophil to lymphocyte ratio as a novel prognostic factor in patients with triple negative breast cancer[J]</article-title><source>Cancer Manag Res</source><year>2019</year><volume>11</volume><fpage>5125</fpage><lpage>5131</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S195324</pub-id><pub-id pub-id-type="pmid">31213922</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Xuan Q, Yang Y, Ji H et al (2019) Combination of the preoperative albumin to globulin ratio and neutrophil to lymphocyte ratio as a novel prognostic factor in patients with triple negative breast cancer[J]. Cancer Manag Res 11:5125&#x02013;5131<pub-id pub-id-type="pmid">31213922</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y-T</given-names></name><name><surname>Kuo</surname><given-names>L-T</given-names></name><name><surname>Lai</surname><given-names>C-H</given-names></name><etal/></person-group><article-title>Low pretreatment albumin-to-globulin ratios predict poor survival outcomes in patients with head and neck cancer: a systematic review and meta-analysis[J]</article-title><source>J Cancer</source><year>2023</year><volume>14</volume><issue>2</issue><fpage>281</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.7150/jca.80955</pub-id><pub-id pub-id-type="pmid">36741261</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Wang Y-T, Kuo L-T, Lai C-H et al (2023) Low pretreatment albumin-to-globulin ratios predict poor survival outcomes in patients with head and neck cancer: a systematic review and meta-analysis[J]. J Cancer 14(2):281&#x02013;289<pub-id pub-id-type="pmid">36741261</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Jia</surname><given-names>X</given-names></name><etal/></person-group><article-title>Prognostic value of the albumin-to-globulin ratio in patients with colorectal cancer: a meta-analysis[J]</article-title><source>Nutr Cancer</source><year>2022</year><volume>74</volume><issue>9</issue><fpage>3329</fpage><lpage>3339</lpage><pub-id pub-id-type="doi">10.1080/01635581.2022.2076890</pub-id><pub-id pub-id-type="pmid">35622391</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Quan L, Jiang X, Jia X et al (2022) Prognostic value of the albumin-to-globulin ratio in patients with colorectal cancer: a meta-analysis[J]. Nutr Cancer 74(9):3329&#x02013;3339<pub-id pub-id-type="pmid">35622391</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><etal/></person-group><article-title>Low Pretreatment albumin-to-globulin ratio predicts poor prognosis in gastric cancer: insight from a meta-analysis[J]</article-title><source>Front Oncol</source><year>2020</year><volume>10</volume><fpage>623046</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.623046</pub-id><pub-id pub-id-type="pmid">33575220</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Wei C, Yu Z, Wang G et al (2020) Low Pretreatment albumin-to-globulin ratio predicts poor prognosis in gastric cancer: insight from a meta-analysis[J]. Front Oncol 10:623046<pub-id pub-id-type="pmid">33575220</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Simmonds</surname><given-names>PC</given-names></name><name><surname>Primrose</surname><given-names>JN</given-names></name><name><surname>Colquitt</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies[J]</article-title><source>Br J Cancer</source><year>2006</year><volume>94</volume><issue>7</issue><fpage>982</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6603033</pub-id><pub-id pub-id-type="pmid">16538219</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Simmonds PC, Primrose JN, Colquitt JL et al (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies[J]. Br J Cancer 94(7):982&#x02013;999<pub-id pub-id-type="pmid">16538219</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Carlomagno</surname><given-names>C</given-names></name><name><surname>De Stefano</surname><given-names>A</given-names></name><name><surname>Rosanova</surname><given-names>M</given-names></name><etal/></person-group><article-title>Multiple treatment lines and prognosis in metastatic colorectal cancer patients[J]</article-title><source>Cancer Metastasis Rev</source><year>2019</year><volume>38</volume><issue>1&#x02013;2</issue><fpage>307</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1007/s10555-018-9748-7</pub-id><pub-id pub-id-type="pmid">30003458</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Carlomagno C, De Stefano A, Rosanova M et al (2019) Multiple treatment lines and prognosis in metastatic colorectal cancer patients[J]. Cancer Metastasis Rev 38(1&#x02013;2):307&#x02013;313<pub-id pub-id-type="pmid">30003458</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>Y-D</given-names></name><name><surname>Yu</surname><given-names>G-Y</given-names></name><etal/></person-group><article-title>Integrated omics of metastatic colorectal cancer[J]</article-title><source>Cancer Cell</source><year>2020</year><volume>38</volume><issue>5</issue><fpage>734</fpage><lpage>747.e9</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2020.08.002</pub-id><pub-id pub-id-type="pmid">32888432</pub-id>
</element-citation><mixed-citation id="mc-CR88" publication-type="journal">Li C, Sun Y-D, Yu G-Y et al (2020) Integrated omics of metastatic colorectal cancer[J]. Cancer Cell 38(5):734-747.e9<pub-id pub-id-type="pmid">32888432</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>X-J</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Cai</surname><given-names>C-D</given-names></name><etal/></person-group><article-title>The generation and validation of a 20-genes model influencing the prognosis of colorectal cancer[J]</article-title><source>J Cell Biochem</source><year>2017</year><volume>118</volume><issue>11</issue><fpage>3675</fpage><lpage>3685</lpage><pub-id pub-id-type="doi">10.1002/jcb.26013</pub-id><pub-id pub-id-type="pmid">28370286</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Xie X-J, Liu P, Cai C-D et al (2017) The generation and validation of a 20-genes model influencing the prognosis of colorectal cancer[J]. J Cell Biochem 118(11):3675&#x02013;3685<pub-id pub-id-type="pmid">28370286</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><mixed-citation publication-type="other">Lu Y, Zhou X, et al (2021) Prognosis prediction for colorectal cancer patients: a risk score based on the metabolic-related genes[J]. Int J Med Sci 18(3):801</mixed-citation></ref></ref-list></back></article>